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Abstract 
 
The vertebrate immune system uses pattern recognition receptors (PRRs) to detect a 
large variety of molecular signatures (pathogen associated molecular patterns - 
PAMPs) from a broad range of different invading pathogens. The PAMPs range in 
size from relatively small molecules, to others of intermediate size such as bacterial 
lipopolysaccharide, lipopeptides and oligosaccharides, to macromolecules such as 
viral DNA, RNA and pathogen-derived proteins such as flagellin. Underlying this 
functional diversity of PRRs is a surprisingly small number of structurally distinct 
protein folds that include leucine-rich repeats in Toll-like receptors (TLRs) and Nod-
like receptors (NLRs), the DExH box helicase domain in RIG-like receptors (RLRs), 
and CTL domains in the C-type lectins. Following PAMP recognition by the PRRs, 
downstream signaling pathways activate the innate immune system to respond to 
invading pathogenic organisms. The resulting stimulatory response is also vital for a 
balanced adaptive immune response to the pathogen, mediated by circulating 
antibodies and/or cytotoxic T cells. However, an aberrant stimulation of the innate 
immune system can also lead to excessive inflammatory and toxic stress responses. 
Exciting opportunities are now arising for the design of small synthetic molecules that 
bind to PRRs and influence downstream signaling pathways. Such molecules can be 
useful tools to modulate immune responses, for example, as adjuvants to stimulate 
adaptive immune responses to a vaccine, or as therapeutic agents to dampen aberrant 
immune responses, such as inflammation. The design of agonists or antagonists of 
PRRs can now benefit from a surge in knowledge of the three dimensional structures 
of PRRs, many in complexes with their natural ligands. This review article describes 
recent progress in structural studies of PRRs (TLRs, NLRs, C-type lectins and RLRs), 
which is required for an understanding of how they specifically recognize structurally 
diverse "foreign" PAMPs amongst a background of other "self" molecules, sometimes 
closely related in structure, that are present in the human body. 
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1. Introduction to pattern recognition receptors 
The immune system has evolved to protect organisms as diverse as plants, flies and 
animals against infection by invading microorganisms. A critical first step in 
achieving this protection is to quickly recognize when infectious agents are present; 
the immune system must distinguish what is foreign (or “non-self”) from what is 
normally present in the body (i.e. “self). It is the main function of the innate immune 
system to provide this rapid surveillance, using germ-line encoded proteins called 
pattern recognition receptors (PRRs)§ [1-4]. PRRs function by recognizing "danger 
signals" and then initiating an appropriate innate immune response. Danger signals 
can be derived from both foreign pathogens as well as endogenous sources, such as 
lysed cells. The PRRs comprise four main families of proteins, some membrane-
bound and others soluble cytoplasmic proteins that recognize molecules (or molecular 
patterns) associated with microbes – so-called pathogen-associated molecular patterns 
(PAMPs). The activation of PRRs by binding to PAMPs initiates intra-cellular 
signaling cascades and altered patterns of gene expression that lead to a rapid first line 
defense against the invading microorganism, as well as promoting activation and 
maturation (more slowly – over days to weeks) of the adaptive immune system. The 
adaptive immune response is mediated mainly by B and T cells. Signals from the 
innate immune system drive the selective expansion and activation of B and T cell 
populations with specificity for the infectious agent, optimized through cycles of 
somatic mutation and selection (Figure 1) [5]. The main effector mechanisms of 
adaptive immunity include the production of antibodies by B cells (to act as blocking 
antibodies, or as opsonins for complement- and phagocyte-mediated killing), and the 
killing of infected host cells by cytotoxic T cells. In addition, activation of adaptive 
immunity results in the production of memory B and T cells, which can provide long 
term specific protection  (e.g. over years to a whole life time) against subsequent 
infections by a pathogen bearing the same antigens [6, 7]. 
Adherence of microbes to the surface of cells of the innate immune system, 
mediated through binding of PAMPs to cell surface PRRs, actively promotes 
ingestion of the microbe and entrapment and digestion within phagosomes. On the 
other hand, soluble cytoplasmic PRRs act as sensors for intracellular pathogens. 
Through PAMP-PRR interactions, innate immune cells are activated and respond by 
producing inflammatory cytokines and chemokines that trigger responses from other 
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cell types. Furthermore, activation of the innate immune system leads to deployment 
of a range of killing factors to attack invading pathogens. These include bactericidal 
enzymes, toxic chemicals such as reactive oxygen and nitrogen species, and 
antimicrobial peptides (e.g. defensins). The detection of certain PAMPs may also 
activate the complement system, a cascade of triggered enzyme reactions that can lead 
to tagging (or opsonization) of the microbe surface with the complement protein C3b, 
which marks it out for destruction by other components of the immune system. 
Finally, PRR-PAMP interactions stimulate cells of the adaptive immune system, 
including antigen-presenting cells (APCs), such as dendritic cells (DCs) and B- and 
T-cells. DCs reside in a quiescent state in peripheral tissues, where they continuously 
sample their environment by phagocytosis and pinocytosis. DCs are equipped with a 
suite of PRRs for binding to PAMPs, thereby facilitating rapid up-take of pathogens 
by phagocytosis. Inside APCs, foreign proteins are digested into peptide fragments, 
which include some that act as T cell epitopes. A dramatic increase in the expression 
of surface MHC-I and -II is elicited by PAMP-PRR binding. This leads to enhanced 
surface presentation of T cell peptide epitopes in complexes with the membrane 
bound MHC molecules, ready for recognition by T-cell receptors.  
Immature DCs are relatively non-motile, but after activation they become 
highly motile and migrate through the lymphatic system, carrying pathogen-derived 
antigens to secondary lymphoid tissues, such as the lymph nodes. Circulating naïve B 
and T lymphocytes also halt in the lymph nodes, where they scan APCs and intact 
antigens draining through in interstitial fluids from peripheral tissues. Intact antigens 
can be recognized by B-cell receptors (BCRs) on the surface of B cells. Viruses and 
bacteria typically display a repetitive and closely spaced array of epitopes across their 
surface. Such an arrangement of epitopes is specifically recognized as foreign by B-
cells [8]. This occurs through cross-linking of multiple BCRs by multivalent binding 
to surface arrays of antigens, which generates a powerful activation signal, and 
initiates the process of B-cell activation and maturation [9]. The activated B and T 
cells then interact within the lymph nodes in a process that leads to the production of 
antibody-secreting B cells and cytotoxic T cells optimized to recognize and remove 
foreign pathogens. The activated B and T cells also harbor PRRs, and are further 
stimulated by repeated interaction with PAMPs during the course of the adaptive 
immune response [10]. PAMP-PRR interactions thus play a key role in immune 
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responses to invading pathogen, from its beginnings through into the later stages of 
maturation of the adaptive immune response (Figure 1). For this reason, both natural 
and synthetic ligands of PRRs are now attracting great interest as immune modulators 
in the fields of vaccinology and immunotherapy [6, 11-13]. 
PRRs can be divided into four main families, based upon their structural 
features as well as the type of PAMP they recognize [14]. These include the Toll-like 
receptors (TLRs), the C-type lectin receptors (CLRs), NOD-like receptors (NLRs), 
and RIG-like helicase receptors (RLRs). A review of newly described PRRs appeared 
recently [15]. 
 
1.1  Toll-like Receptors 
One of the major families of PRRs are the TLRs, so named because of their homology 
with the Toll receptor, first discovered in the 1980’s in the fruit fly Drosophila [16, 
17]. The Toll receptor plays a role in the development of the dorsoventral body axis in 
Drosophila, acting as a cell-surface receptor for the cytokine ligand Spätzle [18]. 
Later it was discovered that Toll and related receptors also function in the innate 
immune response to fungal and bacterial infection in the fruit fly, stimulating the 
release of defensins and related antimicrobial peptides [19]. As genome sequencing 
advanced, about 10 directly homologous receptors were later discovered in 
vertebrates, and these became known as the Toll-like Receptors (for a recent historical 
account see [20]). The ligands for most of these receptors are now known. The 
ligands display remarkable structural diversity, and include bacterial peptidoglycan, 
lipoproteins, lipopolysaccharide (LPS), mycobacterial lipoarabinomannan, yeast 
zymosan, bacterial flagellin, as well as pathogen-derived nucleic acids [21]. 
 To date, 10 TLRs have been reported in humans and 13 in mice. The TLRs are 
type I integral membrane glycoproteins that are located either in the outer cell 
membrane (TLR1, 2, 4, 5, 6, 10, 11, 12), or in endosomal membranes with their 
ectodomains facing the internal space of the endosome (TLR3, 7, 8, 9, 13) (Figure 2). 
They contain an N-terminal extracellular domain (ECD) of between 550-800 residues, 
a single helical transmembrane domain of ≈20 residues, and a C-terminal intracellular 
signaling domain of ≈180 residues, called a “Toll IL-1 receptor” (TIR) signaling 
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domain, because it shares homology with the signaling domains of IL-1R family 
members. The crystal structure of the TIR domain of TLR1/2 was published in 2000 
[22]. Some TLRs act as heterodimers, including TLR1/2 and TLR2/6, which respond 
to different bacterial lipoproteins. All TLRs share a common basic 3D architecture, 
with multiple leucine-rich repeats (LRRs) arranged in a horseshoe or crescent-shaped 
structure that together comprises the N-terminal ectodomain responsible for PAMP-
binding. A single trans-membrane segment links the ectodomain to the C-terminal 
domain, which interacts with adapter proteins in the cytoplasm, an event that 
culminates in activation of transcription factors, such as NFκB and members of the 
interferon-regulated factors (IRF) family, which in turn leads to altered patterns of 
gene expression [23, 24]. 
 
1.2. C-Type lectin receptors (CLRs) 
The C-type lectin receptor (CLR) superfamily is a large group of proteins that are 
widely distributed in Nature [25, 26]. C-type lectins are Ca2+-dependent carbohydrate-
binding proteins that contain one or more C-type lectin (or lectin-like) domains 
(CTLDs), with related folds dictated by a common sequence motif. When such 
domains bind to carbohydrate, they are called carbohydrate recognition domains 
(CRDs). A CRD is present in all Ca2+-dependent lectins, but not in other (Ca2+-
independent) types of animal lectin. A recent review grouped the CTLDs into 17 
different classes [25]. Of special interest here are the class-II asialoglycoproteins on 
APCs that function as PRRs in the innate immune system. These type-II membrane 
receptors contain a short cytoplasmic domain, a single transmembrane segment, and 
an ectodomain comprising a stalk region involved in oligomerization, which is linked 
to one or more CRDs. Professional APCs, such as macrophages, DCs and B cells, are 
equipped with receptors that collectively allow them to recognize, capture and 
internalize foreign antigens. Besides the B-cell receptor found only on B cells, other 
APCs use germline encoded membrane proteins for detecting foreign antigens that 
include Fc receptors, complement receptors, the TLRs, and the CLRs. TLRs are not 
able to promote internalization of antigens, whereas this is an important function of 
CLRs. Representatives of the class-II CLRs are ICAM-3, DC-SIGN, MGL, 
LANGERIN, MINCLE, DECTIN-2, BDCA-2, DCIR and DCAR. The class V CLRs 
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are also known as type-II natural killer (NK) cell receptors, and include DCAL-1, 
DCAL-2 and dectin-I. Finally, the class-VI CLRs include the mannose receptor (MR) 
and lymphocyte antigen 75 (DEC-205). 
 CLRs are important in immune recognition of glycoproteins and cell wall 
glycolipids derived from viruses and microbes, and mediate pathogen uptake and 
phagocytosis [27, 28]. However, the biological functions of CTLs are more complex 
than just facilitating antigen uptake by DCs. Many of the carbohydrates recognized by 
CLRs are not unique to pathogens but can also be found on many self-glycoproteins 
[27]. Hence, self and non-self structures may be recognized by CLRs, which is a 
reflection of the multiple and complex functions these receptors, as a whole, have in 
the maintenance of immune homeostasis [29-32]. Ligand binding to these receptors 
can also activate signaling pathways that modulate TLR signaling, activate innate 
immune responses, and influence adaptive immune responses [30, 31].  
 The C-type (calcium-dependent) lectin (CTL) family of proteins is found on 
the surface of cells of the innate immune system, including macrophages and DCs [28, 
29, 33]. The membrane bound CTLs bind oligosaccharides, in particular, containing 
D-mannose and L-fucose residues, using highly conserved carbohydrate recognition 
domains (CRDs). Many CTLs on APCs contain only a single CRD, well-known 
examples being DC-SIGN, DCIR, MGL and Langerin. Others, such as DEC-205 and 
the mannose receptor (MR), possess 8-10 CRDs within their extracellular regions [25, 
34-36]. According to their carbohydrate specificities, CLRs tend to be classified as 
eithe mannose/fucose- or galactose-recognizing lectins. Some CLRs share 
carbohydrate ligands. For example, the trisaccharide Lewisx can serve as a ligand for 
DC-SIGN and the MR. However, ligand promiscuity is also seen, for example, with 
DC-SIGN, which is able to recognize efficiently different Lewis-type epitopes as well 
as high-mannose glycans. CLRs have now become attractive targets for ligand design, 
for use in targeting antigens to DCs and for modulating antigen-specific immune 
responses [28, 29, 33]. 
 
1.3. NOD-like receptors (NLRs) 
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The nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) 
function as intracellular surveillance sensors to detect microbial products and danger 
signals inside cells [37-41]. Some NLRs are also involved in inflammatory responses 
and apoptosis, and thus as a whole the NLRs mediate diverse biological functions in 
innate immunity [39, 42-46]. NLR family members are found in plants, invertebrates 
and mammals, although NLR structure and function has been most thoroughly studied 
in mice and humans [47]. The NLRs are sub-divided into five subfamilies, into which 
the 22 human NLRs are grouped as follows; NLRA (CIITA), NLRB (NAIP), NLRC 
(NOD1, NOD2, NLRC3, NLRC4, NLRC5, NLRP and NRLX), NLRP (NLRP1-14) 
and NLRX (NLRX1) (Figure 3) [48]. Some NLRs activate a proinflammatory 
response (such as NOD1 and NOD2), others form a large multiprotein complex called 
an inflammasome [47, 49] resulting in cleavage of procaspase-1 and formation of 
activated caspase I (NLRP1, 3, 6, 7 and 12, and NLRC4), others provide 
immunoregulatory functions (NLRC3 and 5, CIITA and NLRP10), while others have 
roles in development (NLRP2, 5, 7 and 14) [48, 50]. 
 The NLRs are soluble cytoplasmic proteins, important for sensing infectious 
agents that have gained access to the interior of the cell [48, 50-52]. There are 22 
NLRs in humans and 34 in mice [53], which exhibit characteristic multi-domain 
structures, typically consisting of a central nucleotide binding domain (NBD) that 
contains a NACHT and other sub-domains, an N-terminal effector binding domain 
most commonly a CARD (caspase activation and recruitment domain), a BIR 
(baculovirus inhibitor repeat) or a pyrin (PYD) domain, and a C-terminal putative 
ligand-binding domain comprising multiple leucine-rich repeats (LRRs) (Figure 3) 
[39, 40, 48]. The effector domains bind downstream signaling molecules, ultimately 
leading to activation of protein kinases, transcription factors, proteases and other 
components of host defense and inflammatory responses [38, 50]. 
 Some of the PAMPs detected by NLRs have been identified. For example, 
NOD1 and NOD2 sense fragments of peptidoglycan (PGN) [37]. Macrophages 
contain intracellular hydrolases that digest bacterial PGN. NOD1 detects a minimal 
PGN fragment containing γ-D-glutamyl-meso-diaminopimelic acid that is found 
almost exclusively in Gram-negative bacterial PGN [54]. On the other hand, NOD2 
detects muramyl-dipeptide (MurNAc-L-Ala-D-isoGln), which is a common motif in 
PGN in almost all bacteria [55, 56]. NLRP3 and NAIP respond to a remarkably 
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diverse set of PAMPs [39], whereas NLRC4 senses bacterial flagellin [57, 58], and 
NLRX1 binds to RNA [59].  
 
1.4. RIG-like helicase receptors (RLRs) 
How does a cell distinguish viral nucleic acid (RNA) in the cytoplasm from its own? 
An important clue came by recognizing that viral RNA is structurally different, in 
ways that mark it out as foreign to the cell. Thus, dsRNA is virtually absent in 
mammalian cells, whereas some viruses generate dsRNA, as a byproduct of viral 
RNA replication, containing transiently an uncapped 5'-triphosphate group. Cellular 
primary transcripts also contain 5'-triphosphate, however, many self-RNAs undergo 
processing steps that remove or mask the 5-triphosphate moiety. For example, 
mRNAs are capped by methylation at the 5'-terminus, tRNAs undergo cleavage of 5'-
PPP groups before they reach the cytoplasm, and ribosomal RNAs form complexes 
with ribosomal proteins. The retinoic acid-inducible gene-I (RIG-I)-like receptors 
(RLRs) are constitutively expressed in the cytoplasm of most cells, including DCs and 
macrophages as well as non-immune cells, where they act as cytosolic sensors of viral 
RNA [60, 61].  
 RLRs provide a first line of defense against infection by RNA viruses, 
including influenza, rift valley, measles, vesicular stomatitis and hepatitis C viruses 
[61]. There are three members of the RLR family; RIG-I (also known as DDX58), 
"melanoma differentiation associated factor gene 5" (MDA5), and "laboratory of 
genetics and physiology 2" (LGP2). Recognition of the 5'-PPP terminus unique to 
viral RNA, either in a dsRNA or a hairpin-looped structure, a so-called pan-handle-
like RNA, is an important function of RIG-I [62, 63]. The prototypical ligand of RIG-
I is a short RNA with a blunt-ended base-paired and uncapped 5'-triphosphate 
terminus. Until very recently, much less was known about the nature of RNAs 
recognized by MDA5. MDA5 generally responds to long dsRNA molecules. 
However, RIG-I and MDA5 may also be activated by self-RNAs that are cleaved by 
RNaseL. The function of the third RLR, called LGP2, has been less well studied, but 
seems to participate in RIG-I and MDA5-dependent antiviral responses [60, 61]. 
 11 
 RIG-1 and MDA-5 possess a conserved central helicase-like domain, linked to 
two N-terminal caspase activation and recruitment domains (CARDs), and a Zn2+-
containing C-terminal domain (CTD) (Figure 4). LGP2 has similar domain 
architecture, although it contains no CARD domains. The ligands that function as 
RLR activators are typically virus-specific RNA structures, including 5’-triphosphate 
linked to single stranded or blunt-ended double stranded RNA, as well as poly I:C (a 
synthetic analog of viral dsRNA). Upon binding to such PAMPs, RIG-1 initiates a 
signaling cascade that induces innate immune defenses and inflammatory cytokines to 
establish an antiviral state [64]. However, knowledge of the complex regulatory 
mechanisms that control signaling through these PRRs is incomplete. Aberrant RIG-1 
signalling can lead to apoptosis, altered cell differentiation, inflammation, 
autoimmune disease and cancer. Apart from RLRs, several other members of the 
helicase superfamily have been proposed to participate in intracellular sensing of 
pathogen-derived nucleic acids, including DDX1/3/21/36, DHX9/36 and STING [60]. 
 
2. Structures of Toll-Like Receptors (TLRs) 
2.1. Overview 
 Several reviews on TLR structural biology have been published recently [16, 
65, 66]. TLR ECDs are constructed of tandem copies of a structural motif known as 
the leucine-rich repeat (LRR). LRRs are found in several thousand proteins involved 
in a wide variety of physiological functions in all kingdoms of life, including immune 
responses, signal transduction, cell-cycle regulation and enzyme regulation (for 
reviews see [67-69]). These proteins typically contain 2-40 tandem LRR modules, 
which form curved horseshoe or solenoid-like structures that seem to be well suited 
for protein-protein and protein-ligand interactions. The 10 human TLRs contain 19-25 
LRR modules. Each LRR typically contains a ≈20-30 residue consensus sequence 
(Figure 5A), which includes the characteristic motif LxxLxLxxNxL (x = any amino 
acid), although other hydrophobic residues can substitute for Leu, and other amino 
acids capable of donating hydrogen bonds (T, S, C) can substitute the Asn residues 
[67, 70]. Each LRR module adopts a folded structure comprising one ß-strand that 
includes the entire consensus motif, followed by a bridging loop that often contains 
helical and/or turn-like elements that folds back over the ß-strand thereby burying the 
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hydrophobic L residues (Figure 5A). The bridging loop is linked to the ß-strand of the 
next LRR, which is aligned so that the ß-strands form a regular hydrogen-bonded 
parallel ß-sheet. This arrangement can now be repeated by addition of more LRRs, 
which generates a horseshoe or solenoid-like tertiary structure, as shown in Figure 5B. 
The resulting curved parallel ß-sheet forms the inner concave face of the horseshoe, 
whereas the residues in the adjacent bridging (often helical) loops form the outer 
convex surface of the horseshoe. The ECDs of most TLRs are glycoproteins, in which 
surface exposed Asn residues carry N-linked glycosylation. The side-by-side nestling 
together of LRRs in these proteins ensures that the hydrophobic residues are buried 
internally. The situation is different for the N- and C-terminal LRR modules, where 
one side of the hydrophobic core will not be covered by another LRR module. Instead, 
capping modules are added to the termini (LRR-NT and LRR-CT) (Figure 5C). The 
capping modules do not show the same conserved sequence and structural motifs. 
They typically comprise smaller disulfide-bonded folds that pack across the 
hydrophobic core and leave polar surface residues exposed to the solvent. 
The LRR horseshoe geometries have been characterized by three parameters – 
the radius of the horseshoe arc (“radii” R), the mean rotation angle about the central 
axis relating one ß-strand to the next (“twist”), and the tilt angle of the parallel ß-
strand direction per turn (“tilt”) [68]. The observed values of R, for example, range 
from 1.5 to 4.7 nm, so the arc of LRR family members can possess quite different 
degrees of curvature. LRR family proteins have been sub-divided into seven 
subfamilies based on sequence and structural comparisons. They are “RI-like”, “CC”, 
“bacterial”, “SDS-22-like”, “plant-specific”, “typical” and “TpLRR” [69, 71]. The 
“typical” sub-family includes all the TLRs. However, phylogenetic analyses 
suggested that two distinct sub-classes of "typical" TLRs exist, the single domain and 
the three domain TLR sub-classes, which diverged early in evolution [66, 72]. 
The ECDs of TLR1, 2, 4 and 6 belong to the three domain sub-class [66]. 
These TLRs have two structural transitions in the concave ß-sheet face of the ECD, 
thereby creating N-terminal, central and C-terminal subdomains (Figure 6). The 
central domains have radii, twist and tilt angles that deviate markedly from the 
standard values of the “typical” single domain subfamily members. This appears to be 
caused by several unusual features, including LRRs in the central domain that lack the 
characteristic Asn residue within the consensus motif. This Asn side chain usually 
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interacts in a ladder of hydrogen bonds with surrounding backbone carbonyl oxygens 
thereby stabilizing the horseshoe structure. In addition, the LRR modules of the 
central domains vary in size from 20 to 33 residues, whereas in the N- and C-terminal 
domains, the LRR modules are mostly 24 residues.  The LRR modules in the central 
region have bulkier α-helical segments on the exposed convex face, which take up 
more space, leading in turn to greater curvature and a smaller arc radius in the central 
domain. These structural features are also important for the biological function of 
these TLRs, because the central domains play an important role in binding ligands or 
co-receptors. Although no crystal structure is available, TLR10 also appears to 
contain broken Asn ladders and greater variation in module length in the central part 
of the ECD, and so is also likely to belong to the three-domain sub-family. 
In contrast, TLR3, 5, 7, 8 and 9 belong to the single domain sub-family. Their 
LRR modules have conserved Asn residues within the consensus motif and relatively 
uniform module lengths. Functional and phylogenetic analyses provide support for 
these correlations, which in the cases of TLR3 and 8 is also supported by structural 
(crystallographic) information. TLR7, TLR8 and TLR9 are predicted by sequence 
comparisons to contain “island regions”, comprising substantial domains that loop-out 
of the external surface of the horseshoe architecture [73]. 
Strong evidence exists that active TLRs function as homo- or hetero-dimers, 
and/or as part of supramolecular complexes with other membrane-associated proteins. 
For example, TLR2 signals as a heterodimer in a complex with either TLR1 or TLR6. 
Crystal structures of the ECDs of the TLR1/2 and TLR2/6 heterodimers show how 
specific lipopeptides are recognized by these receptors (vide supra) [74, 75]. In the 
case of the TLR2/6 heterodimer, a plasma membrane protein (CD36) of the class B 
scavenger receptor family, also participates in signaling [76]. Although human TLR3 
ECD is found as a monomer in the crystal structure [77, 78], it binds its target double 
stranded (ds) RNA as a dimer [79, 80]. Moreover, clustering of multiple TLR3 
homodimers may occur at the cell surface through binding to long dsRNAs [79, 81]. 
FRET studies suggest that TLR9 exists as preformed inactive dimers in the cell 
membrane that change conformation upon binding to DNA rich in CpG dinucleotides. 
Ligand binding then results in allosteric changes in the cytoplasmic signaling domains, 
which leads to receptor activation and signaling [82]. TLR5, the only protein-binding 
TLR, responds to a monomeric form of bacterial flagellin that, in oligomeric form, 
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constitutes the flagellar tail responsible for swimming locomotion in ß- and γ-
proteobacteria. A crystal structure of an engineered TLR5-flagellin complex revealed 
a 2:2 subunit stoichiometry, with two TLR5 ECDs in a tail-to-tail organization [83]. 
Finally, TLR4 forms a stable 1:1 heterodimer with MD-2, and the resulting TLR4-
MD-2 complex is responsible for recognition of lipopolysaccharide (LPS) from 
Gram-negative bacteria. Cells transfected with TLR4 are not responsive to LPS, but 
are when complemented with MD-2 [84]. Moreover, another membrane-associated 
protein, CD14, is required for full ligand recognition and signaling through TLR4. 
TLR4 may be organized into a supramolecular complex through interactions with 
MD-2 and CD14 (and perhaps other components) at the cell surface [76, 85, 86]. 
TLRs interact with an unusually diverse variety of ligands. These ligands 
range from naturally occurring highly non-polar lipids, such as LPS and lipopeptides, 
through to polar macromolecules such as DNA, RNA, and the protein flagellin. It is 
also important to remember that the same TLRs from different species may exhibit 
differences in the way they recognize and respond to the same or closely related 
ligands [87]. 
 
2.2  Structures of TLR1/2 and 2/6 
Various earlier reports suggested that TLR2 is able to recognize a diverse array of 
microbial structures, although most are glycolipids (such as lipoteichoic acid (LTA), 
lipoarabinomannan and lipopolysaccharide (LPS)), or lipopeptides/lipoproteins, or 
GPI-anchored structures [88]. However, some purported TLR2 ligands lack clear 
structural relationships to lipidic molecules, such as fragments of peptidoglycan and 
the polysaccharide zymosan isolated from yeast. This led to the suggestion that TLR2 
is a rather “promiscuous receptor” [89]. This view has now changed, with the 
realization that some of the potential ligands tested in earlier studies were isolated 
from biological sources and were likely to contain trace amounts of bacterial 
lipoproteins/lipopeptides [88]. The extent of the analytical problem can be understood 
by noting that some PAMPs may activate PRRs at picomolar (pM) concentrations, 
whereas some cellular studies of TLR2 activation were performed with “purified” 
ligands in the micromolar range. Ideally, ligands of synthetic origin should be tested 
in receptor activation assays, although their structural and stereochemical complexity 
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often makes this difficult. Very recently, structural studies have reinforced the view 
that only lipopeptides/lipoproteins containing Pam2Cys or Pam3Cys (or those with 
related acyl chains (Figure 7)) represent specific ligands of TLR2, recognized by 
heterodimers of TLR1/2 or TLR2/6. In contrast, the lipid anchor in LTA, the GPI-
anchored lipids in lipoarabinomannan as well as related glycolipids frequently found 
in membrane of higher organisms do not activate TLR2 at physiologically relevant 
concentrations [88]. 
Crystal structures have revealed that the TLR1/2 heterodimer binds to 
lipoproteins with a triacylated N-terminus (such as Pam3Cys), while the TLR2/6 
heterodimer binds to lipoproteins with a diacylated N-terminus (such as Pam2Cys). 
All bacterial lipoproteins contain a glycerol moiety linked via a thioether to the side 
chain of an N-terminal Cys residue (S-[2,3-bis(acyloxy)-2R-propyl-cysteinyl), and 
acylated with two long chain fatty acids. Lipoproteins anchored in the membrane of 
Gram-positive bacteria, generally have a free N-terminus. In Gram-negative bacteria, 
however, lipoproteins contain three lipid chains (Figure 7); a third acyl chain is 
attached directly to the N-terminus of the peptide/protein. During the biosynthesis of 
lipoproteins [90]), an inner membrane enzyme (Lgt) transfers the diacylglycerol 
moiety from membrane phospholipids to the N-terminal cysteine residue of the pre-
lipoprotein. The acyl chains are typically palmitoyl groups, although other chain 
lengths and levels of unsaturation are found in different bacteria [90]. Gram-positive 
bacteria generally lack the lipoprotein N-acyltransferase (Lnt) required to attach the 
third amide-linked acyl chain to the N-terminus [91]. Mycobacteria are a special case, 
since they are high GC Gram-positive bacteria, albeit with a special outer layer of 
unique lipid components called mycolic acids covalently linked to the peptidoglycan. 
They contain the Lnt enzyme and so are able to produce tri-acylated lipoproteins 
carrying mycobacteria-specific fatty acids [92]. Mycoplasma, on the other hand, are 
low GC Gram-positive bacteria without cell walls (no PGN or LPS), with a 
cytoplasmic membrane that is stabilized by the presence of sterols and lipoglycan 
(long chain heteropolysaccharides covalently linked to membrane lipids [93, 94]). 
Lipoproteins in the cell membrane of Mycoplasma are of the Pam2Cys variety [95, 
96]. 
The residues immediately downstream of the N-terminal Cys in bacterial 
lipoproteins are variable in sequence, but the first is typically Gly or has a small polar 
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side chain. The following residues appear not to exert a strong influence on signaling 
by the TLR1/2 heterodimer (vide supra) [97-99]. Structure-activity studies with 
triacylated lipopeptides have revealed that the immune modulatory activity is strongly 
dependent on the fatty acid chain length and the correct absolute configuration of the 
natural 2R-dihydroxypropyl-R-cysteine. Also, replacement of the sulfur by CH2 
reduces biological activity significantly [99]. 
 The Gram-positive bacterial membrane is surrounded by a thick cell wall of 
peptidoglycan, so their lipoproteins are typically embedded under this barrier and not 
accessible to cellular receptors. Furthermore, Gram-negative bacteria have an 
asymmetric outer membrane (OM) with a layer of LPS molecules forming the outer 
leaflet and exposed on the outer cell surface; lipoproteins are anchored in the inner 
leaflet of phospholipids and face the periplasm. As a result, lipoproteins in both types 
of bacteria are not immediately accessible for binding to PRRs. This accessibility 
problem is likely solved during the initial stages of the innate immune response, when 
bacterial cells are engulfed by macrophages and undergo phagocytosis with 
subsequent degradation of the cell wall. During this process bacterial lipoproproteins 
are released and can interact with TLRs [90]. 
 
2.2.1. The human TLR1/2 heterodimer  
Lipopeptide ligand is required to induce formation of heterodimers of TLR1 
and TLR2. The full-length receptors on the plasma cell membrane form weakly 
associated homotypic and heterotypic multimers without bound ligand. However,  
lipopeptide binding induces rearrangement to the more stable heterodimer, which then 
initiates signaling [100, 101]. 
 To facilitate production and crystallization of human TLR1 and TLR2, a large 
number of recombinant hybrid fusion proteins were designed and screened to identify 
constructs suitable for crystallization [74, 102]. This approach led to the identification 
of two fusion proteins, called hT1V8 and hT2V9, in which 105 residues from the C-
terminus of human TLR1 and 82 residues from the C-terminus of human TLR2, 
respectively, were replaced with fragments of hagfish variable lymphocyte receptor 
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(VLR). These fusion proteins formed a stable and crystallizable heterodimeric 
complex with the lipopeptide Pam3CysSK4. 
 The structure of the TLR1/2-Pam3CSK4 complex confirmed the horseshoe-
like geometry of each TLR chain [74]. Viewed from the side, the overall shape of the 
complex resembles the letter “m”, with the two C-terminal VLR domains adjacent in 
the middle, but not in direct contact with each other nor with other TLR residues 
(Figure 8). The ECDs of TLR1 and TLR2 contain the distinctive 3 subdomain 
organization (vide infra). The N-terminal domain contains the LRR-NT capping motif 
and LRRs1-4, each with typical 24-residue LRR repeats. The H-bonding Asn ladder 
and a spine formed by consecutive Phe residues are conserved in this region. In 
contrast, the central and C-terminal subdomains have LRR modules with atypical 
sequences and their ß-sheet conformations deviate from those seen in standard LRRs. 
The central subdomain also lacks the Asn ladder and the Phe spline. 
The TLR1/2 chains make contact with each other through LRRs in the central 
domain, near the center of the “m”, where the binding site for the lipopeptide is also 
located. From one orientation, the two ester-linked lipid chains project forwards and 
interact with a pocket on TLR2, whereas the amide-linked lipid chain projects 
backwards and inserts into a narrow channel in TLR1 (Figure 9A/B). The protein-
protein interaction between the two TLR chains extends over 850 Å2, with a near 
circular interface and the bound ligand located near the center. 
 The TLR chains in the heterodimer make contact with each other and the 
lipopeptide ligand through the sides of each horseshoe. An opening is created in the 
side of TLR2 by the presence of a large helical loop that projects up and outwards 
from LRR module 11, thereby allowing the two ester linked lipid chains to insert into 
a deeply buried cavity that extends into the region between the ß-sheet base and the 
bridging helical loops of LRR modules 10-12 (Figure 9C). The two lipid chains 
occupy over 90% of the total solvent accessible volume of the pocket. The lack of an 
Asn ladder and spine of phenylalanine residues within the central LRRs in TLR2 help 
to account for the formation of this deep binding pocket. In a similar fashion, an 
opening between two LRR repeats in the central domain of TLR1 allows the amide-
linked lipid chain to insert into a hydrophobic pocket between LRR modules 11-12. 
This pocket is only one quarter the volume of that in TLR2, but is fully occupied by 
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the amide-linked palmitoyl chain. All three bound lipid chains adopt mostly extended 
conformations, but gauche backbone conformations also exist at some points along 
the lipid backbone. 
 The conserved cysteinyl-glycerol moiety of the ligand exits the TLR1/2 
complex through an opening lying between the two TLR chains. A series of 
hydrogen-bonding interactions between backbone carbonyl oxygen and nitrogen 
atoms of the TLRs and the ligand, as well as complementary surface contacts appear 
to stabilize the complex (Figure 9D). Small amino acids (Gly/Ser) are preferred in the 
second position (after Cys) in bacterial lipoproteins. Consistent with this, the second 
amino acid (Ser) of the synthetic ligand Pam3CSK4 is located in the narrow neck 
region of the binding pocket, where space for a side chain is limited. The side chains 
of the four Lys residues make only limited interactions with TLR1 or TLR2, 
consistent with the low sequence conservation found at these positions in bacterial 
lipoproteins. 
  
2.2.2. The mouse TLR2 monomer  
Crystal structures have also been reported for a mouse TLR2-hagfish VLR fusion 
protein, in complexes with Pam3CSK4 and Pam2CSK4 [74]. The protein is a monomer 
in solution and when crystallized with each lipopeptide ligand. The structures of the 
mouse and human TLR2 ECDs are highly homologous (1.1 Å rmsd over the 
backbone atoms), as expected from their high sequence identity (68%). The two 
different lipopeptides bind to mouse TLR2 in an almost identical fashion, with the 
two ester-linked lipid chains inserted into the lipid-binding pocket. The amide-linked 
peptide chain, however, and the peptide portion of both ligands remain solvent 
exposed and are not visible in the electron density map. An interesting difference is 
found in the shape of the lipid binding pockets of TLR2 between the two species, 
caused by sequences differences in residues lining the binding pocket. The ligand-
binding pocket is slightly shorter in the mouse TLR2 compared to human TLR2. As a 
result, mTLR2 binds shorter lauroyl chains (C12) more efficiently than hTLR2 [103]. 
This is reflected in the ability of lauroyl3CSK4 to activate mouse but not human TLR2 
[104]. Deletion or more marked truncation of the two ester bound lipids abolishes 
TLR2 activation [103]. 
 19 
 Additional structures have been reported of mouse TLR2-VLR fusion proteins 
bound to bacterial lipoteichoic acid from Streptococcus pneumonia (pnLTA), and to 
PE-DTPA, a synthetic derivative of phosphatidylethanolamine linked to a metal-
coordinating DTPA group (1,2-dimyristoyl-sn-glycero-3-phospho-ethanolamine-N-
diethylenetriaminepentaacetic acid) (Figure 7) [75]. Both pnLTA and PE-DTPA bind 
to TLR2, but have little or no ability to activate the receptor. LTA typically contains a 
long chain of ribitol or propanolamine repeating units that are anchored in the cell 
membrane by linkage to a diacylglycerol head group. pnLTA binds to TLR2, but does 
not induce heterodimerization and signalling of TLR1/2 or TLR2/6, consistent with 
the substantially weaker proinflammatory activity of pnLTA compared to bacterial 
lipoproteins. 
 In the monomeric TLR2-pnLTA complex, the overall horseshoe-like shape of 
the ECD and structure of the lipid-binding pocket is unchanged (Figure 10A/B). 
However, the LRR10 and LRR11 surface loops and the position of the ligand head 
group are significantly altered from those in the TLR1/2-Pam3CSK4 and TLR2/6-
Pam2CSK4 (discussed below) complexes. This is perhaps not surprising, given that 
the lipid chains are linked to a peptide chain in Pam2/3CSK4 and to a saccharide chain 
in pnLTA. In the TLR2-pnLTA structure, the position of the sugar head group of 
LTA is translated by ≈5.2 Å and rotated by ≈110o toward the lateral surface of the 
horseshoe-like structure (Figure 10C). 
 PE-DTPA (Figure 7) is a synthetic lipid closely related in structure to the 
abundant phospholipids in cellular membranes. PE-DTPA can bind to TLR2 but 
cannot induce formation of TLR1/2 or TLR2/6 heterodimers. As in other structures 
containing lipid-bound TLR2, the acyl chains of PE-DTPA are inserted into the same 
lipid-binding pocket in TLR2. However, the structure of the LRR11 loops and the 
position of the PE-DTPA head group more closely resemble those seen in the TLR2-
pnLTA complex (Figure 10C). The fact that both pnLTA and PE-DTPA show little or 
no ability to activate TLR2, and adopt similarly shifted head group binding sites, 
suggest that the head group structure plays an important role in heterodimerization 
and hence in TLR2 activation. Bacterial lipopeptides show the strongest TLR2 
stimulatory activity [88] most likely because they induce stable heterodimerization of 
the ECDs of TLR2 with TLR1 or TLR6. 
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2.2.3. The mouse TLR2/6 heterodimer  
To improve protein production and crystallization, C-terminal LRRs in the ECDs of 
mouse TLR2 and mouse TLR6 were replaced with equivalent regions from the 
hagfish VLR. Although the engineered TLR2 and TLR6 hybrids each purify as 
monomeric proteins, they formed a stable heterodimeric complex when incubated 
with the synthetic lipopeptide Pam2CSK4. Binding of the lipopeptide induces the 
formation of a familiar “m”-shaped heterodimer, with the N termini stretched out to 
opposite ends and the C-termini converged in the middle (Figure 11) [75]. 
Heterodimerization of the ECDs in this way likely enforces juxtaposition and 
activation of the intracellular TIR domains. Like the TLR1/2 heterodimer, the 
lipopeptide-binding site in TLR2/6 is located on the sides of each horseshoe at the 
center of the “m” shaped complex. As in the TLR1/2-lipopeptide complex, both ester 
linked lipid chains are inserted through an opening between LRR11 and LRR12 into a 
hydrophobic pocket in TLR2 of ≈1200 Å3 formed by hydrophobic residues from 
LRR9-12 (Figure 12A). The ester-bound lipid chains adopt similar structures when 
bound to TLR2/6 and TLR1/2, but the Me-ends of the chains in the two complexes 
diverge slightly in different directions at the bottom of the binding pockets, most 
likely due to sequence differences between mouse and human TLR2s. 
 Protein-protein interactions between TLR2 and TLR6 are mediated by surface 
exposed residues in modules LRR11-14. The LRR11 and LRR12 loops of both TLR2 
and TLR6 are located at the center of the interface and contribute key hydrophobic 
interactions. The surface area of the hydrophobic core of the TLR2/6 interface is 
increased by ≈80% compared to that in the TLR1/2 complex (Figure 11). These 
hydrophobic contacts are surrounded by a ring of polar hydrogen-bonding and ionic 
interactions. It seems that the more extensive protein-protein interface in the TLR2/6 
heterodimer might help to compensate for the lack of an amide linked lipid chain, 
which should help stabilize the TLR1/2-ligand complex. 
 The structures of the glycerol moiety and the peptide backbones of the ligands 
in the hTLR1/2-Pam3CSK4 and muTLR2/6-Pam2CSK4 complexes can be 
superimposed almost exactly. However, important structural differences are seen in 
the positions of surface residues near the LRR11 loop that influence access to the 
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lipid-binding channels in TLR1 and TLR6, in particular, F317 in TLR6, which 
corresponds to F312 in TLR1 (Figure 12B/C). This region on TLR1 forms the 
opening of the binding site for the amide-linked lipid in Pam3CSK4. In addition, the 
bulky side chains of F343 and F365 in TLR6, buried in the middle of the pocket, 
shorten considerably the lipid-binding channel. As a result, the hydrophobic binding 
pocket in TLR6 is less than half as long as that in TLR1. These changes likely 
contribute significantly to the markedly reduced affinity of the TLR2/6 heterodimer 
for triacylated lipoproteins. Thus, typical amide-bound lipid chains are too long to fit 
into the short TLR6 lipid channel. This conclusion is supported by mutagenesis 
experiments. For example, an F343M and F365L double mutation of TLR6, which 
extend the binding pocket, allowed an almost complete response of the TLR2/6 
heterodimer to triacylated as well as diacylated lipopeptides [75]. 
Other differences between the complexes include a repositioning of surface 
residues in TLR6, which allow a new hydrogen-bonding interaction with the first 
peptide bond of the ligand, which is not seen in TLR1 (Figure 12C). On the other 
hand, many polar and hydrophobic contacts between the polar head group of the 
ligand and TLR2/6 are conserved, and are likely responsible for the strong 
stereospecific recognition by both receptor heterodimers of essentially the same head-
group in both types of lipoprotein/lipopeptide. Using chemically synthesized 
lipopeptides derived from the lipoprotein MALP-2 from Mycoplasma fermentans, it 
was shown that the R stereoisomer (S-[2,3-bis(acyloxy-(2R)-propyl-cysteinyl-
GNNDESNISFKEK]) exhibits much higher specific activity than the S-stereoisomer 
[105]. The side-chains of the first two amino acids (CS) in the ligand also make polar 
interactions with TLR2/6 (Figure 12C), and in both cases a small side chain is favored 
in the second position. The side chains beyond the second residue, however, appear to 
have higher flexibility in the crystalline state and form only weak interactions with the 
TLRs. Nevertheless, these side chains are located within ≈0.5nm of the TLRs and 
might still be able to interact weakly with the receptors [97, 106]. 
 
2.2.4. Applications of TLR1/2 and TLR2/6 agonists 
 There is now great interest in the discovery of novel small molecule TLR 
modulators, because of their potential immune stimulatory activity and value as 
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adjuvants in immunotherapy [107-115]. Several TLR2 ligands have undergone 
clinical testing in vaccine formulations [116]. For example, a synthetic lipopeptide 
related to the naturally occurring MALP-2 lipoprotein is currently in clinical trials in 
combination with the nucleoside analog gemcitabine for the treatment of pancreatic 
cancer [117, 118]. The lipopeptide should activate DCs to express co-stimulatory 
molecules and promote type-1 T helper responses. This lipopeptide is diacylated and 
so interacts with TLR2/6. The structure of the complex is expected to be very similar 
to that with the synthetic ligand Pam2CSK4, since only the peptide side chain after 
Ser2 are different between the two lipopeptides. 
 
2.2.5. Accessory proteins involved in TLR2 signaling 
The mechanism(s) by which TLRs recognizes PAMPs on the cell surface appears to 
involve additional membrane-associated accessory proteins [119].  For example, 
CD36 was shown by mutagenesis to play an important role in signaling through TLR2 
on macrophages by the diacylated lipopeptide MALP2 [120]. CD36 is a member of 
the scavenger receptor type B family, and has been implicated in the recognition of 
oxidized LDL particles and the uptake of fatty acids. CD36 also appears to facilitate 
recognition of diacylated lipoproteins by TLR2/6. CD36 has an established role in the 
recognition of endogenous ligands and might therefore represent a signaling bridge 
between endogenous ligands and the PRRs of the innate immune system [121]. No 
structural data is available so far for CD36, and no direct binding studies with 
lipopeptides have been reported. 
Another mediator of lipoprotein signaling is the GPI-anchored glycoprotein 
CD14, which is highly expressed on monocytes, macrophages and neutrophils. CD14 
is best known for its role in sensitizing cells to the presence of Gram-negative 
bacterial LPS, by delivering this molecule to the TRL4 signaling complex (vide infra). 
Membrane-bound CD14 shuttles LPS to TLR4 complexes, whereas a soluble form of 
CD14 enables cells that lack endogenous CD14 to respond to LPS [122, 123]. 
However, CD14 is also capable of binding to a wide variety of natural and synthetic 
acylated ligands, in addition to LPS. For example, CD14 has been shown to enhance 
cellular inflammatory responses to a variety of acylated agonists of TLR2, including 
bacterial lipoproteins. The binding of soluble CD14 to Pam3CSK4 has been 
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demonstrated with affinities in the low micromolar range. Moreover, CD14 was 
shown to enhance signaling by triacylated lipopeptides through the TLR1/2 
heterodimer in a whole cell assay [124]. It was suggested that binding of triacylated 
lipopeptides to CD14 may be the first step in the signaling pathway through TLR1/2. 
After binding of lipopeptide, the complex with CD14 should interact with TLR1 and 
TLR2 at the cell surface, with transfer of the lipopeptide to the signaling-competent 
TRL1/2 heterodimer complex [125]. Recent in vitro studies support roles for CD14 
and LPS-binding protein in driving binding of TLR1/2 to lipoproteins [126]. 
The crystal structures of mouse and human CD14 have been reported, 
although the latter structure is only to 0.4 nm resolution [127, 128]. Both proteins 
contain ≈11 tandem LRRs, and adopt an overall horse-shoe-like shape typical of 
related LRR-family members. The binding site for LPS on CD14 has been intensively 
studied by mutagenesis and by epitope mapping of antibodies that block LPS binding 
[129]. This study highlighted a region near the N-terminus, which contains a large 
hydrophobic pocket, likely for LPS binding, and possibly also for binding related 
lipophilic ligands such as triacylated lipopeptides. A co-crystal structures of CD14 
bound to one of its lipophilic ligands has not yet been reported, and it is so far unclear 
structurally how CD14 interacts with TLR1/2. 
 
2.3 Structures of TLR3 
Double-stranded RNA (dsRNA) is a molecular pattern associated with viral infection 
that is specifically recognized by TLR3. dsRNA is produced by most viruses at some 
point during their replication, although dsRNA of non-viral origin has also been 
shown to stimulate TLR3 signaling. Other receptors, however, are also capable of 
responding to viral dsRNA in mice and humans, indicating a redundancy in 
mechanisms used to recognize this PAMP [130]. Binding of dsRNA to TLR3 leads to 
stabilization of a homodimeric TLR3-dsRNA complex that signals via TIR domains 
facing the cytoplasmic side of the endosomal membrane (Figure 2). TLR3 consists of 
an ECD containing multiple LRRs, a single transmembrane domain and an 
intracellular TIR domain. TLR3 is distinct from other TLRs in that it does not depend 
upon MyD88, but rather uses TRIF for signaling [131]. The TRIF-induced 
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intracellular signaling pathway leads to activation of genes for secreted antiviral 
immunostimulatory cytokines, in particular, the type-I interferons. 
 The horseshoe-like shape of the TLR3 ECD was first revealed in crystal 
structures of the monomeric protein [77, 78]. The large curved solenoid has an inner 
diameter of ≈4.2 nm and an outer diameter of 9 nm (Figure 13). As with other LRR 
proteins, the concave inner face consists of a large parallel ß-sheet, composed of ß-
strands from 23 adjacent LRRs. The solenoid has a rather flat surface, devoid of any 
twist. At its N-terminus, the LRR-NT motif consists of a disulfide cross-linked ß-
hairpin, whereas the C-terminal capping domain (LRR-CT) forms a compact folded 
structure stabilized by two disulfide bridges. 
 dsRNA, but not dsDNA nor single-stranded (ss)-RNA, induces 
homodimerization of the purified TLR3 ectodomain [79]. The minimum length of 
RNA needed for binding and homodimerization is ≈45 bp, and the pH optimum for 
binding is below 6.0, likely reflecting the slightly acidic environment inside 
endosomes. A crystal structure of the TLR3-dsRNA complex contains the bound 
RNA in a typical A-DNA-like double helical structure, sandwiched between the two 
TLR3 ectodomains (Figure 14A) [80]. The overall structure of the ectodomain in the 
dimer complex is not changed significantly from that of the monomeric form. The 
homodimeric complex again has an overall “m” shape, with the N-termini at the outer 
sides and the C-termini converging at the center of the “m”. However, the mechanism 
of ligand recognition is unique. In the TLR3-dsRNA complex, the straight rod-shaped 
ligand makes contact with both TLR3 chains at the outer N-termini (LRR-NT and 
LRR1-3 modules) and at the inner C-termini (LRR19-21 and the LRR-CT modules). 
The distance between the N-terminal binding sites is ≈14 nm, which corresponds to 
about 3.5 helical turns of RNA. This explains why the length of the RNA double helix 
needs to be at least ≈45 bp on each strand. Mostly the phosphodiester backbone 
makes critical interactions with both TLR3 chains, whereas the base-pairs, and hence 
the sequence of the RNA, does not (Figure 14B). This is consistent with the known 
sequence independence of RNA binding to TLR3. The only place where the two 
TLR3 monomers make direct contact with each other is through largely polar side 
chains in the centrally located LRR-CT modules, but the interface surface area is only 
574 Å2. 
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 dsRNA molecules both shorter and longer than ≈45bp can bind to TLR3, 
although for shorter dsRNAs the affinity is much reduced [79]. It seems likely that 
multiple TLR3 dimers can bind to very long dsRNA molecules. However, a different 
mode of interaction has been proposed to account for binding of short ≈20 nt dsRNA 
molecules to TLR3, although the models remain to be confirmed by structural 
analyses [132]. The binding of various synthetic analogues of dsRNA to TLR3 has 
been studied [133], including so-called polyI:C, which consists of a chain of 
polyriboinosine (poly I) hybridized with a complementary strand of polyribocytosine 
(Figure 15). PolyI:C was initially discovered as a potent inducer of type I interferons 
(IFNs) [134]. A less-toxic analogue is poly(I:C12U), containing a uridine at every 13th 
monomer position. As an inducer of IFN, poly(I:C12U) has potent antiviral and 
immunomoduatory properties, which arise due to its ability to signal through TLR3 
[135]. Poly(I:C12U), under the names Ampligen and Rintatolimod (Hemispherex 
Biopharma), has been developed clinically as an experimental immunomodulatory 
dsRNA drug [118]. A closely related immunostimulatory drug under development is 
Poly-ICLC, which contains PolyI:C stabilized with poly-lysine (called Hiltonol, 
Oncovir Inc.) [116]. 
 
2.4 Structures of TLR4 
TLR4 and the co-receptor MD-2 comprise the physiological receptor for LPS. LPS is 
a complex glycolipid and the major component of the outer leaflet in the OM of most 
Gram-negative bacteria (Figure 16). The structure of LPS is highly variable, not only 
between different Gram-negative bacteria and different strains of the same bacteria, 
but can also vary within one strain depending upon growth conditions [136]; for 
example depleting metal ions in the media, or growth in the presence of cationic host 
defense peptides (products of the innate immune system) can lead to rapid 
modification of LPS [137]. However, a common "lipid A" moiety can be recognized 
in all LPS molecules, which contains a bis-glucosamine disaccharide to which are 
typically attached 5-6 ester- and amide-linked lipid chains, as well as two phosphate 
groups, and sometimes other polar groups, such as phosphatidyl-ethanolamine (PE) 
and 4-amino-4-deoxy-L-arabinose (Ara4N) (Figure 16). Lipid A is not found 
naturally, but is released from LPS by mild acid hydrolysis. The lipid A moiety is 
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linked to a carbohydrate core domain, typically comprising ≈6-8 sugar residues, 
including Kdo (3-deoxy-D-manno-oct-2-ulosonic acid) and Hep (L-glycero-D-
mannoheptose) that are not generally found on mammalian cells. The core domain is 
then linked either to a long oligo-saccharide chain or to a highly immunogenic O-
antigen polysaccharide, composed of repeat units that can be highly variable between 
different serotypes. The O-antigen is the most exposed segment of LPS on the 
bacterial cell surface. Overall, the LPS layer in the OM constitutes a major 
permeability barrier, which severely restricts diffusion of substances (e.g. antibiotics) 
across the OM and into the bacterial periplasm and cytoplasm. 
 LPS can stimulate a powerful immune response by signaling through TLR4. If 
the response is overwhelming and uncontrolled, this immune protection mechanism 
can lead to fatal septic shock. LPS is extracted from the bacterial membrane and 
transferred to TLR4 by two accessory proteins, the LPS binding protein (LBP) and 
CD14 [119]. Membrane-bound CD14 shuttles LPS to TLR4/MD-2 complexes at the 
cell surface, whereas a soluble form of CD14 enables cells that lack endogenous 
CD14 to also respond to LPS [122, 123]. Early work showed that the lipid A region is 
responsible for most of the immunostimulatory activity of LPS. The number of lipid 
chains has a large influence on inflammatory activity. Lipid A with 6 lipid chains has 
optimal inflammatory activity, whereas with five chains the lipid A is ≈100 fold less 
active. With only four lipid chains, as found in lipid IVa and Eritoran (vide supra), the 
glycolipid typically has antagonist activity [138]. The mouse TLR4 complex appears 
to be more promiscuous in recognizing different forms of lipid A than is human TLR4, 
and seems even to interact with the anti-cancer drug taxol [139]. However, minor 
changes in LPS structure can have large effects on immunostimulatory activity, and 
even abolish endotoxic effects [140, 141]. 
 
2.4.1. The human MD-2 /Lipid IVa complex 
MD-2 is a ≈18 kDa secreted glycoprotein, which alone, as well as in the complex with 
TLR4, binds LPS with nanomolar affinity [85]. The number and length of the acyl 
chains have an important influence on signaling through the TLR4/MD-2 complex. 
For example, E. coli lipid A is usually hexa-acylated and acts as a potent activator 
(agonist) of all mammalian cells. In contrast, tetra-acylated lipid A such as lipid IVa 
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(Figure 16), the biosynthetic precursor of E. coli LPS, acts as an agonist on mouse 
and as an antagonist (with antiendotoxic) activity on human cells [142]. Lipid IVa 
does not induce formation of the human TLR4/MD-2 heterodimer complex, as 
required for signaling activity. 
 The first structural insight into how lipid A is recognized by MD-2 came from 
crystal structures of human MD-2 bound to lipid IVa [143]. MD-2 comprises a single 
immunoglobulin domain stabilized by three disulfide bonds. The protein consists of 
two ß-sheets, one of three antiparallel ß-strands and the other of six antiparallel ß-
strands (Figure 17A). Between the two sheets is a large, hydrophobic cavity with a 
volume of ca. 1710 Å3. The overall structure is rather like a partly open clam, with the 
two shells represented by the two ß-sheets. The four lipid chains of the ligand insert 
through the opening into the main body of the clam. In a crystal structure of MD-2 
without bound lipid IVa, the MD-2 structure is not altered significantly; the lipid A 
binding pocket is still present, but is occupied by three myristic acid molecules that 
appear to have been co-purified and co-crystallized with MD-2. The lipid chains at 
positions-2 and -3 in lipid IVa are mostly fully extended and reach far into the 
hydrophobic binding pocket of MD-2 (Figure 17B). The 2’ and 3’ lipid chains have a 
distinctly curved conformation. The fatty acid chains in the cavity are packed next to 
each other and interact through van der Waals contacts. The size of the hydrophobic 
binding cavity is not large enough to accommodate the two additional lipid chains 
present in lipid A (and LPS). Rather, one of the additional lipid chains is found on the 
surface of MD-2 where it forms part of the contact interface with TLR4 in the 
TLR4/MD-2/LPS complex (vide supra). 
 The 1- and 4’-phosphate groups and the two sugar residues in lipid IVa are at 
the solvent exposed surface, in the opening of the clam-like structure. Here, hydrogen 
bonding interactions occur between amide and ester carbonyls of the ligand and the 
edge of the ß7 strand in the 3-stranded ß-sheet (Figure 17C). Residues from Phe119-
Gly123 are important for LPS recognition, and these residues with the exception of 
Lys122 are highly conserved in MD-2. Overall the entrance to the hydrophobic cavity 
has a positive electrostatic surface, which likely aids binding of the negatively 
charged ligand. However, neither of the phosphate groups is involved in close 
electrostatic contacts with atoms of MD-2. 
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2.4.2. The human TLR4/MD-2 with bound Eritoran 
Eritoran (or E5564) is a synthetic molecule related to the lipid A of the nonpathogenic 
LPS of Rhodobacter sphaeroides, with antagonist activity on human TLR4/MD-2. 
Eritoran contains a bis-glucosamine backbone linked via amide or ether bonds to four 
lipid chains, one containing a cis-double bond, as well as two phosphate groups 
(Figure 16). However, neither Eritoran nor lipid IVa induces formation of the 
TLR4/MD-2 dimeric signaling complex (vide supra). The human MD-2 was 
crystallized with a hybrid hTLR4-hagfish-VLR fusion protein as a stable 1:1 complex, 
with Eritoran bound to MD-2 (Figure 18) [102]. All four lipid chains in Eritoran are 
buried inside MD-2 and so are not available for interactions with TLR4. The 
glucosamine backbone in lipid IVa and Eritoran are superimposable when bound to 
MD-2. The shape of the lipid-binding pocket on MD-2 is essentially unchanged in the 
complexes with the two antagonists. Eritoran was in clinical development for use as a 
therapeutic against severe sepsis, however, the compound was recently withdrawn 
following inconclusive phase III trials [111, 118]. 
 
2.4.3. The human TLR4/MD-2/LPS complex 
LPS is extracted from the bacterial membrane and transferred to TLR4/MD-2 by 
LPS-binding protein and CD14. The crystal structure of the TLR4/MD-2/LPS 
complex has been very valuable in understanding ligand binding specificity and the 
mechanism of receptor activation. Interestingly, the signaling complex seen in the 
crystal structure is composed of two copies of TLR4/MD-2/LPS arranged in a 
symmetrical fashion (Figure 19) [144]. 
 The two TLR4 chains each adopt a horseshoe-like shape, as seen with other 
TLRs, resembling in the complex the letter “m”, with both C-termini in the center and 
the N-termini located at each side of the “m” (Figure 19). The two TLR4 chains 
contact each other in the center through LRR modules 15-17.  MD-2 again has a 
clam-like shape composed of two antiparallel ß-sheets, between which the 
hydrophobic lipid chains of LPS can bind. The two MD-2 chains are situated close to 
the center of each arm of the “m”. Each MD-2 makes contact with the side of one 
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TLR4 chain and the exposed convex face of the other TLR4 chain. The numbering 
system used for the lipid chains (R2, R3, R2’, R3’, R2” and R3”) of the lipid A 
moiety is shown in Figure 16. 
 Five of the 6 lipid chains of the lipid A are completely buried inside the 
hydrophobic pocket on MD-2, between the two ß-sheets. However, the R2 chain is on 
the surface of MD-2 (Figure 20A). This composite (protein+lipid) surface forms a 
largely hydrophobic interface with one TLR4 chain (TLR1). Hence this lipid chain, 
and its key position, are likely important for the stability of the complex. Some of the 
ester and amide groups connecting the lipid chains to the sugar residues of lipid A 
interact at the surface of MD-2 with one exposed ß-strand in the 3-stranded ß-sheet. 
The two phosphate groups of lipid A do not appear to occupy specific binding pockets, 
but sit on the surface, close to a positively charged patch formed by Lys residues on 
TLR42 and MD-2, with one phosphate close to an Arg side chain contributed by the 
TLR4 chain. An extended loop protruding from LRR module 9 on the concave face of 
TLR42 forms part of an extensive protein-protein interface (PPI) with MD-2 (Figure 
20B). Finally, another extensive PPI is found between the C-terminal regions of both 
TLR4 chains at the center of the “m” formed by LRR modules 15-17. 
Apart from the lipid A moiety, five additional sugar residues are seen in the 
complex, interacting in particular with a Tyr and several other side chain from TLR42 
(Figure 20C). However, the Kdo III sugar of the inner core of LPS and all 
carbohydrates in the outer core are not clearly visible in the electron density map, 
presumably due to disorder resulting from a lack of fixed interactions in the crystal 
lattice. 
Of special interest is a comparison of the TLR4/MD-2/LPS signaling complex 
with structures of MD-2 bound to the two antagonists, Eritoran and lipid IVa, which 
reveal similarities as well as some key differences. The structures of MD-2 bound to 
the two antagonists reveal a large hydrophobic pocket completely filled by the four 
lipid chains of each antagonist. The size of the pocket is unchanged in the TLR4/MD-
2/LPS complex, although the LPS now has six lipid chains. In order to create 
additional space for lipid binding, the bis-glucosamine backbone is displaced upwards 
by ≈0.5 nm, which repositions the phosphate groups such that they can interact with 
positively charged residues of both TLR4 chains (Figure 21). This appears to be 
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important for dimerization and activation of the complex. However, the bis-
glucosamine backbones of the two antagonists are not only translated, but also rotated 
by ≈180o, thereby interchanging the positions of the two phosphate groups. The two 
phosphate groups in the lipid A greatly influence the endotoxic activity of LPS [145]. 
Deletion of either phosphate group reduces endotoxic activity by ≈100 fold. The 
resulting monophosphoryl lipid A (MPL) is only a weak activator of the innate 
immune response. An MPL based upon lipid A from Salmonella minnesota was 
shown to selectively activate the less inflammatory TLR4-TRAM-TRIF intracellular 
signaling pathway rather than the TLR4-Mal-MyD88 pathway [146]. Hence, lipid A 
modifications can influence innate immune responses by mediating the recruitment of 
distinct sets of adaptor proteins in the cytoplasm. These results suggest that the MPL 
ligand has not only a lower affinity, but it also induces a structural rearrangement of 
the TLR4-MD-2 receptor complex. The effects are likely mediated by the observed 
interactions of the 1- and 4’-phosphate groups with a cluster of positively charged 
side chains from TLR41, TLR42 and MD-2. This likely explains why deletion of one 
phosphate can have a major impact on the LPS-receptor interaction. It is also 
interesting to note that many bacteria have evolved enzymes that alter their lipid A 
structure, not only by modifying the number of acyl chains but also by attaching other 
polar/charged groups to the phosphates (such as phosphatethanolamine and 4-amino-
4-deoxy-L-arabinose). Such modifications have a major influence on the host 
response elicited by bacteria, and may be an important factor in determining the 
outcome of infectious disease [139]. 
Efforts to understand the lipid A-TLR4 interaction have already yielded 
improved vaccines. Whereas strong induction of the MyD88 pathway is harmful 
because of high production of pro-inflammatory cytokines, such as TNF-α and IL-1ß, 
a low level of induction is beneficial for long lasting immunity elicited by vaccines. 
One MPL derivative has recently been approved as an adjuvant in vaccines used 
worldwide [147]. Furthermore, the development of a wide variety of different 
immunostimulatory lipid A derivatives for vaccine and other therapeutic applications 
is continuing to attract great interest [107, 110, 114, 118]. 
  
2.4.4. The mouse TLR4/MD-2/-LPS and -lipid IVa complexes 
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It was mentioned above that tetra-acylated lipid IVa shows weak agonist activity on 
mouse but antagonist activity on human cells. As discussed above, the human 
TLR4/MD-2/lipid IVa complex is a monomeric unit in the complex, whereas the 
signaling-competent hTLR4/MD-2/LPs complex is dimeric in the crystal. Recently, 
the crystal structures of mouse TLR4/MD-2 with bound hexaacylated LPS (from E. 
coli) and with lipid IVa were reported [148], which allow interesting comparisons to 
be made with the human receptor. 
The mTLR4/MD-2/LPS complex also appears as a dimeric unit in solution 
and in the crystalline state, confirming that LPS binding induces dimerization of the 
TLR4/MD-2 complex for immune signaling (Figure 22A). In contrast, the 
mTLR4/MD-2/lipid IVa complex appeared monomeric in solution, but in crystals a 
dimeric form of the mTLR4/MD-2/lipid IVa complex was observed (Figure 22B). 
The appearance of the dimer when the mouse receptor is bound to lipid IVa correlates 
with the weak agonist activity seen with this ligand in mice. It seems that the 
dimerization interaction of two 1:1:1 mTLR4/MD-2/lipid IVa complexes is weak in 
solution, but is favored upon crystallization. Conceivably, dimerization might also be 
enhanced at the cell surface, compared to free solution, as a result of membrane 
anchoring, and additional interactions between the transmembrane and/or cytoplasmic 
domains of TLR4. 
Of special interest in the dimeric mTLR4/MD-2/lipid IVa complex, is the 
orientation of the phospho-glucosamine backbone of lipid IVa and the location of the 
lipid chains (Figure 22B/C). Lipid IVa has the same orientation in the mouse complex 
as that seen for lipid A in the complex with LPS, and not that seen in the human MD-
2/lipid IVa complex (Figure 21 and Figure 22C). Moreover, in the complex with lipid 
IVa bound to hMD-2, all four lipid chains are buried in the internal lipid-binding 
cavity inside MD-2. In the complex with mTLR4/MD-2, however, one of the acyl 
chains (R2) is displaced towards the surface of MD-2, leaving part of the hydrophobic 
lipid-binding pocket in MD-2 unoccupied. The R2 chain can then form part of the 
hydrophobic surface of MD-2 that interacts with a hydrophobic patch on TLR4, like 
that seen in the complex with LPS (Figure 22C). It seems that the different 
hydrophobicities of the dimerization interfaces, and the different charge distributions 
of residues on mouse and human TLR4/MD-2 have a decisive influence upon the 
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position and orientation of bound lipid IVa, inducing the agonist orientation with 
mouse TLR4/MD-2 and antagonist orientation with human TLR4/MD-2 [148]. 
 
2.5. Structure of TLR5 
Gram-positive and Gram-negative bacteria swim by rotating helical flagella filaments 
up to 15 µm long extending from their external surface. The rotary motor at the base 
of the filament is embedded in the membrane (or IM) and drives rotation. The 
filament is mostly a helical assembly of a single protein, flagellin (FliC), which forms 
a tubular structure comprising 11 strands of protofilaments. The protofilaments 
contain nearly longitudinal helical arrays of flagellin. Flagellin is, therefore, one of 
the most abundant proteins on the surface of many bacteria. 
 The crystal structure of a 41 kDa Salmonella flagellin fragment (residues 53-
450 of the 494 residue FliC) that does not form filaments, revealed not only the 
structure of the monomer, but also the likely packing of monomers into pairs of 
antiparallel straight supercoiled protofilaments in the crystalline state [149]. The FliC 
structure has an overall boomerang-like shape, which can be divided into three 
domains (Figure 23). One wing of the boomerang is the D1 domain, which comprises 
three α-helices and an extended ß-hairpin, where two helices (αND1a, αND1b) and 
the hairpin are contributed by the N-terminus and the third helix (αCD1) by the 
extreme C-terminus of the protein. Domain D2 at the center of the boomerang also 
comprises two segments (Lys177-Gly189 and Ala284-Ala401) and is largely 
composed of ß-structure. A central fragment from Tyr190-val283 makes up domain 
D3 and the other wing of the boomerang. Since neither vertebrates nor plants contain 
flagella, the presence of flagellin serves as a marker of bacterial infection in both 
classes of organism. TLR5 is the major pattern recognition receptor used to detect 
flagellin, and is the only protein-binding TLR that is conserved in organisms as 
diverse as fish, flies, plants and mammals [150]. TLR5 signals through the adaptor 
protein MyD88. Activation of the receptor mobilizes the pro-inflammatory nuclear 
transcription factor NF-κB in epithelial cells, monocytes and dendritic cells, and 
stimulates TNF-α production. 
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 Recently the crystal structure of an engineered zebrafish TLR5 ectodomain in 
a complex with a truncated fragment of Salmonella FliC was reported [83]. The 
chimeric receptor contains 14 N-terminal LRR modules fused to a C-terminal 
fragment of hagfish VLR. In the TLR5-FliC complex, the FliC D1 domain is located 
on the lateral side of one TLR5 chain forming an extensive 'primary binding interface' 
that defines a 1:1 heterodimer (Figure 24A/B). Two such heterodimers further 
oligomerize to a symmetric 2:2 complex, where TLR5 from the first heterodimer 
makes additional, less extensive interactions with both FliC’ and TLR5’ from the 
second heterodimer, so forming a 'secondary dimerization interface' (Figure 24A/B). 
Thus flagellin binding results in the assembly of two TLR5 chains into a tail-to-tail 
organization that juxtaposes the C-terminal regions in the center, as seen in the “m”-
like structures formed by other TLR-ligand complexes. However, the ligand-receptor 
stoichiometry and ligand binding arrangement observed is unique to the TLR5 
signaling complex. The FliC-TLR5 interface also coincides with residues involved in 
FliC oligomerization in the flagellar filament structure, and is therefore well 
conserved across bacterial species. 
 The chimeric TLR5 ectodomain consists of an N-terminal ß-hairpin-capping 
motif (LRR-NT), 13 complete LRR modules, and two residues from LRR14. Only 
domain D1 of flagellin is involved in direct contacts with TLR5. The primary 
interface is formed between one side of the three long helices of FliC in domain D1 
(αND1a, αND1b and αCD1) and a lateral surface of TLR5 comprising LRRNT to 
LRR10, with 1320 Å2 of buried accessible surface area on each side (Figure 24D). 
This interface can be described as two adjacent, spatially separated surfaces, denoted 
sub-interfaces A and B (and A' and B') (Figure 24B). The interface A/A' has 530 Å2 
buried surface area provided by LRRNT to LRR6, with mainly hydrophilic 
interactions, with five H bonds and three salt bridges. The sub-interface B/B' is 
provided by LRR7-10 on TLR5 and the upper part of αND1a and αND1b on FliC. 
This interface is also mainly hydrophilic and is largely located in a protruding loop in 
LRR9 that undergoes structural rearrangement upon FliC binding. An LRR9-loop 
deletion mutant of TLR5 is severely impaired in FliC binding [83]. Overall, residues 
in domain D1 make substantial contributions to both high affinity binding and TLR5 
signaling. The conserved D1 domain is exposed in monomeric flagellin but is buried 
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in the polymerized flagellin fibre, suggesting that TLR5 recognizes flagellin 
monomers that are released upon depolymerization of flagellin fibres. 
 A secondary dimerization interface contains interface α (TLR5-FliC), its 2-
fold symmetry related interface α’ (TLR5-FliC’), and interface ß (TLR5-TLR5’) 
(Figure 24B/C). No direct contacts are seen between the two FliC molecules in the 
complex. Dimerization interface α is located on the convex side of TLR5’ LRR12/13 
and on the FliC C-terminal αND1b region and following loop at the bottom of the D1 
domain. Dimerization interface ß, with 550Å2 buried surface area, is formed mainly 
by the two TLR5 chains, on the ascending lateral side of LRR12/13. 
 There has been great interest in exploiting the TLR-flagellin interaction to 
design new vaccine adjuvants, and antagonistic therapeutics for hyperinflammatory 
diseases. For example, the protein drug CBLB502 is a pharmacologically optimized 
derivative of Salmonella flagellin, designed for use as a radioprotectant in cancer 
radiotherapy by acting as a TLR5 agonist with reduced immunogenicity and toxicity 
[151]. This drug contains the complete domains D0 and D1 formed by N- and C-
terminal regions of flagellin (1-176 and 402-505), linked by a flexible 16 residue Gly-
rich linker. This construct includes the three long helices (αND1a, αND1b and 
αCD1) and ß-hairpin present in domain D1. The construct can be produced in E. coli 
and retains the NF-κB-inducing activity and stability of flagellin, but is substantially 
less immunogenic. In another example, flagellin has been fused genetically to various 
protein antigens to generate chimeric fusion proteins that are significantly more 
immunogenic than achieved simply by mixing the antigen with flagellin [152-154]. 
This approach exploits the adjuvant activity expected from a TLR5 agonist, including 
induction of DC maturation, and up-regulation of cytokines, co-stimulatory signals 
and antigen-presenting molecules [155]. 
 
2.6. TLRs 7, 8 and 9 
TLRs 7, 8 and 9 are involved in the recognition of viral and bacterial nucleic acids, 
and like TLR3 are located in endosomal membranes with the ectodomains facing 
inside the endosome. This localization is important in directing responses to 
pathogens while avoiding activation by self nucleic acids in the cytoplasm. Indeed, 
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recognition of self-nucleic acids by these TLRs can contribute to the pathology of 
autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus 
[156]. Perhaps most striking is the complex pathway by which these TLRs are 
transported from the endoplasmic reticulum to endolysosomal compartments, a 
pathway that includes an essential processing step by endosomal proteases, involving 
cleavage of the ectodomain within the so-called Z-loop [157-159]. 
 The amino acid sequences of TLRs 7, 8 and 9 suggest that they form a sub-
family, with structural features different from the TLRs discussed above. Each 
ectodomain contains >800 residues comprising about 25 LRRs, with large insertions 
in LRRs 2, 5, 8, 11, 18 and 20 after each consensus ß-strand. These insertions form 
loop structures that are predicted to protrude onto the same lateral face of the receptor 
[70, 160]. In addition, each ectodomain contains an insertion of ≈30 residues between 
LRR14 and 15, called the Z-loop. The ectodomains of these TLRs are cleaved within 
the Z loop by an endosomal protease with the result that no full-length protein is 
usually detectable in the endosome compartment where ligand recognition occurs 
[157-159]. 
Both TLR7 and TLR8 recognize uridine- and guanosine-rich single stranded 
RNA (ssRNA) from various viruses, as well as small interfering RNAs [161, 162]. 
However, TLR7 and 8 also mediate the recognition of self-RNA that is released from 
dead and dying cells, and so contribute to the pathogenesis of autoimmune diseases. 
Several small-molecule activators of TLR7 and TLR8 have also been discovered [163, 
164]. For example, imidazoquinoline derivatives, such as resiquimod (R848) are 
recognized by human TLR7 and TLR8 [164], whereas guanosine nucleotide analogs 
such as loxoribine and other imidazoquinolines, such as imiquimod (R837), activate 
TLR7 (but not TLR8) (Figure 25) [163, 165, 166]. These imidazoquinolones are some 
of the smallest TLR ligands known, and are attractive therapeutic agents for various 
infectious diseases. By activating immune cells they induce the synthesis of IFN-α 
and other cytokines in a variety of cell types. As TLR activators, they have potent 
anti-viral and anti-tumor properties [163]. Imiqimod  (R837) has been approved for 
treatment of external genital warts caused by human papillomavirus, actinic keratosis, 
and basal cell carcinoma, and is also under investigation for treatment of other cancer 
types. Resiquimod (R848) was under development for the treatment of genital herpes, 
but these efforts were suspended in late clinical trials due to inadequate efficacy [113]. 
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TLR9 recognizes single stranded DNA with unmethylated CpG (the p simply 
denotes the phosphodiester bond) sequences, which are under-represented and 
selectively methylated in the mammalian genome and therefore serve to alert DCs to 
the presence of viral and bacterial DNA [2, 167, 168]. In mice, optimal immune 
activation requires a CpG motif flanked by two 5' purines and two 3' pyrimidines (e.g. 
GACGTT), whereas in humans the optimal motif is GTCGTT [169, 170]. CpG DNA 
is known to be an excellent immune adjuvant in various murine disease models and to 
drive a TH1 immune responses. Synthetic CpG oligodeoxynucleotide (ODN) agonists 
for TLR9, therefore, have great potential in therapy [170, 171]. Several classes of 
CpG ODNs are known, varying in nucleotide sequence, single or double stranded, 
varying CpG content and content of phosphorothioate internucleotide linkages. Class 
B CpG ODNs have attracted most interest clinically. They are single stranded and 
fully phosphorothioated in order to confer resistance to nuclease degradation and 
promote ODN uptake. B-ODNs are now in late stage clinical trials as vaccine 
adjuvants to enhance immune responses against infectious diseases and cancer [171]. 
It is well established that activation by CpG ODNs requires TLR9, but it was unclear 
how B-ODN administered externally gains access to the receptor ectodomain inside 
lysosomes. Recent studies suggest that DEC-205 (CD205) is a key cell surface 
receptor involved in the uptake of B-ODN, thereby facilitating stimulatory activity in 
DCs and B cells [172]. 
Before ligand binding, TLRs 7-9 exist as preformed dimers. Ligand binding 
then causes conformational changes that result in receptor activation [82]. This 
preformed dimer model contrasts with the ligand-induced dimerization mechanisms 
seen with other TLRs [74, 75, 80, 83, 144]. After ligand binding to the ectodomains, 
downstream signaling is initiated and transmitted to the nucleus, first through 
recruitment of the cytoplasmic adaptor molecule MyD88. Finally, the transcription 
factors NF-kB and AP-1 are activated, which leads to up-regulation of 
proinflammatory cytokine genes, including those for TNFα, IL-6 and IL-12. In 
addition, signaling can occur via IFN-regulatory factors, which leads to IFN-α gene 
transcription. However, the TLR types in different cell types can respond to agonists 
in different ways, resulting in diverse proinflammatory cytokine production profiles. 
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2.6.1. Structure of TLR8 
Recently the first crystal structure of a member of this TLR sub-family was 
reported, that for human TLR8, both as unliganded preformed dimer and as a ligand-
induced activated dimer [160]. The complete ectodomain of hTLR8 (residues 27-827) 
used for crystallization appears as two fragments of 60 kDa and 50 kDa by SDS 
PAGE, corresponding to N-terminal (res. 27-457) and C-terminal (res. 458-827) 
fragments, due to Z-loop cleavage inside the producing cells (Figure 26). However, 
the fragments of each chain remain associated in the native purified protein. 
Rather than having the horseshoe-like shape seen for the TLRs described so 
far, the number of LRRs in each ECD of TLR8 is large enough to generate a complete 
ring structure with inner and outer diameters of 3.5-4.5 nm and 7-8 nm, respectively 
(Figure 26A). Residues at the N-terminus of TLR8 thus interact directly with others at 
the C-terminus of the ECD through hydrogen bonding and hydrophobic contacts. The 
overall shape is rather like a doughnut with a single cut and with the ends remaining 
in close proximity. The inner concave face comprises a circular ß-sheet structure, 
formed by association of the ß-strands in each LRR. This face is decorated with 
several glycans attached to conserved Asn side chains. Interestingly, the Z loop 
contains the part of the LRR that would normally exist as a loop/helical segment on 
the outer convex face of the doughnut. However, the cleavage site is located at the N-
terminal side of the Z loop, which allows the main ≈24 residue portion of the loop to 
tuck back under the inner concave face, rather than being situated on the outer convex 
face (Figure 26A). As a result, on the convex face LRR13 interacts directly with 
LRR15. At the C-terminal end of the Z-loop, a single turn of α-helix occurs, which is 
stabilized by a disulfide bridge between Cys479 and Cys509 (within LRR16). In the 
unliganded TLR8 dimer, the two doughnut-shaped ECDs bind to each other face-on-
face (Figure 26B), with only a small transposition so that the holes in each doughnut 
are not exactly lined-up. The C-terminal regions of the two TLR8 monomers are 
separated by ≈5.3 nm, which likely precludes proper association of the cytoplasmic 
domains; therefore this dimeric structure should represent the unactivated form of 
TLR8. The insertions in LRRs 2, 5, 8, 11, 18 and 20 after each consensus ß-strand 
form loop structures that protrude to the same lateral face of the ECD. Upon 
formation of the receptor dimer, these loops on both ECDs are buried at the dimer 
interface. 
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The crystal structures of TLR8 in complex with three different small molecule 
agonist ligands (CL097, CL075 and R848 (Figure 25)) were also determined [160]. 
Essentially the same dimeric structure of TLR8 was observed in each of the three 
complexes. The two TLR8 chains within one dimer are essentially superimposable 
(RMSD of 0.04 nm). Upon ligand binding, however, the two C-termini in the dimer 
are brought into closer proximity (≈3 nm) (Figure 26C), which would likely enable 
the intracellular TIR domains to interact optimally and initiate downstream signaling. 
The dimerization interfaces of the unliganded and ligand-induced dimers buries 
≈1290 Å2 and ≈2150 Å2 of accessible surface area on each side, with much of the 
difference accounted for by a ligand-mediated interface (Figure 27). Ligand-induced 
local conformational changes occur predominantly in surface loops of LRR5, LRR8 
and LRR17-20. The protein-protein interface involves loops on LRR5, LRR8 and 
LRR14-20, with both van der Waals, hydrophobic and hydrogen bonding interactions. 
The ligand-mediated interface is composed of residues in LRR11-14 and LRR16-18. 
Two ligand molecules in each complex interact with the TLR8 dimer at the 
dimerization interface at positions related by a non-crystallographic two-fold axis. 
The first is close to LRR11-14 and LRR16*-18* and the second is close to LRR11*-
14* and LRR16-18. Contact with each ligand is made by multiple residues from 
TLR8 and TLR8*, including face-to-face pi-stacking between the side chain of 
Phe405 and a benzene ring in the ligand (R848, CL097 and CL075). Several 
hydrogen bonds are also detected between heteroatoms in the heterocyclic ligands and 
residues in TLR8 (Figure 27). The 2-propyl (CL075) or 2-ethoxymethyl (CL097 and 
R848) substituents of the ligands protrude into a small hydrophobic pocket on TLR8. 
These hydrophobic interactions may be important for the agonist activity of ligands 
targeting TLR8, since R837, an imidazoquinoline similar to R848 specifically 
activates TLR7 but not TLR8, and lacks the 2-substituent in the imidazole ring. 
Ligand binding leads to a reorganization of the dimer structure, and the way in 
which the doughnuts and individual LRR modules interact (Figure 28). In the 
unliganded (inactivated) form, the interactions of LRR8 and LRR18*, as well as 
LRR11-13 and LRR14*-15* are the major contributors to the dimerization interface. 
After ligand binding LRR8 changes its interaction partner to LRR18*-20*, LRR18* 
to LRR11, and LRR11-13 to LRR17*-18*. Concomitantly, Phe405 in LRR13, which 
makes contact with Phe494* in LRR15* in the unliganded form, now interacts with 
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the ligand in the liganded form. In addition, after ligand binding new interactions 
between LRR5 and LRR20* are created. This rearrangement of the complex upon 
binding of relatively small non-natural ligands is quite remarkable. The aromatic 
ligands are much smaller than the natural PAMPs the receptor has evolved to detect. 
Intriguingly, mutations in the receptor that abolish or reduce agonist activity of the 
small ligands, also abolished or reduced significantly signaling by ssRNA, suggesting 
that the small ligands and ssRNA share the same binding site on TLR8. However, 
other TLR8 side chains that surround the small-molecule binding site (Arg429, 
Tyr353, Val378) are not essential for binding the small molecule ligands, yet their 
mutation abolishes binding to ssRNA. So far, it remains unclear exactly how ssRNA 
interacts with the TLR8 dimer. Further structural studies are needed to resolve this 
problem. 
 
2.7. TLRs 10, 11, 12 and 13 
So far 10 different TLRs have been identified in humans, and 13 in mice. As yet, no 
ligand has been identified for TLR10 from either species. However, TLR10 has been 
shown to form homodimers, and to interact with TLRs 1 and 2 [173]. The crystal 
structure of the intracellular TIR domain of human TLR10 has been reported, in the 
form of a symmetric dimer most likely corresponding to the signaling competent form 
[174]. TLR11 and TLR12 are both murine TLRs located in endosomal compartments, 
which are required to mount an effective protective response against the protozoan 
parasite Toxoplasma gondii and other phylogenetically related microorganisms. These 
TLRs, working as heterodimers, can recognize profilin-like proteins in these parasites 
[175, 176]. TLR13 is another endosomal murine TLR, which is involved in 
recognition of microbial nucleic acids, in particular, a conserved bacterial 23S 
ribosomal RNA sequence that includes the binding site of macrolide (e.g. 
erythromycin), lincosamide, and streptogramin group (MLS) antibiotics in Gram-
positive bacteria, like S. aureus [177, 178]. Moreover, modifications to the MLS 
sequence that give rise to resistance to these antibiotics in bacteria, fail to stimulate 
TLR13, thereby linking mechanisms of antibiotic resistance with defective immune 
stimulation via TLR13 [178]. 
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3.  Structures of C-Type lectin receptors 
3.1. Structures of DC-SIGN and DC-SIGNR 
DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-Grabbing 
Nonintegrin) is a prototype type II transmembrane C-type lectin found on 
macrophages and DCs. There it interacts with endogenous molecules, such as ICAM-
2 and ICAM-3, as well as pathogen-associated ligands found on bacteria and viruses. 
DC-SIGN mediates endocytosis and targeting of foreign antigens to late 
endosomal/lysosomal compartments for degradation and presentation to T cells. 
These interactions are mediated through carbohydrates, including N-linked high-
mannose structures (typically 5-9 terminal mannose units such as Man9GlcNAc2), and 
branched fucosylated oligosaccharides that are common on parasites. Signaling 
through DC-SIGN influences cytokine production levels in response to binding 
pathogen-derived carbohydrates [32]. Furthermore, cooperation between innate 
signaling pathways mediated by different PRRs, such as the CLRs and TLRs, plays an 
important role in tailoring adaptive immune responses to different pathogens. On the 
other hand, DC-SIGN mediated internalization is exploited by some pathogens to gain 
entry to target cells. For example, DC-SIGN is exploited by HIV-1, Ebola and 
Dengue viruses as well as by M. tuberculosis to facilitate entry to cells [179-182]. 
Thus, carbohydrate recognition by DC-SIGN is important for both normal immune 
responses and opportunistic exploitation of the receptor by pathogens. 
 DC-SIGNR (or L-SIGN) is a closely related transmembrane receptor found on 
endothelial cells [183]. DC-SIGN and DC-SIGNR share 77% sequence identity and 
are closely similar in overall architecture. However, DC-SIGNR binds only to high 
mannose oligosaccharides, and does not mediate uptake and degradation of 
glycoconjugates. Thus, whereas DC-SIGN functions both in adhesion and in 
endocytosis of pathogens, DC-SIGNR has only the properties of an adhesion receptor 
and with a more restricted set of ligands. However, DC-SIGNR can also serve as an 
entry-receptor for many of the same viruses that exploit DC-SIGN. 
 DC-SIGN and DC-SIGNR consist of an intracellular N-terminal domain for 
signaling in the cytoplasm and a globular C-terminal CRD that binds carbohydrate 
ligands. The CRD is separated from the transmembrane region by a neck domain that 
contains multiple tandem repeats (Figure 29). The neck domain is required for 
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tetramerization, which is mediated through a coiled coil that forms a parallel 4-helix 
bundle. This coiled-coil neck region generates stable tetramers and projects the CRDs 
in a cluster some distance away from the cell surface. However, the CRDs appear not 
to be held in a fixed position but can reorient to engage with carbohydrate ligands 
[184]. The coiled coil contains a heptad repeat sequence (denoted abcdefg, where a/d 
are mostly hydrophobic residues), which is embedded within multiple tandem repeats 
of a largely conserved 23-mer motif (Figure 29) [183]. The side-chains of the 
hydrophobic (a/d) residues within each heptad are buried at the center of the four-
helix bundle. Each motif also contains a conserved proline residue that is predicted to 
interrupt regular helical structure.  Crystal structures of the neck region of DC-SIGNR 
revealed a series of four-helix bundles, connected by short non-helical linkers 
containing the conserved prolines (Figure 30) [185-187]. 
 Crystal structures of the CRDs from DC-SIGN and DC-SIGNR bound to a 
pentasaccharide (GlcNAc1ß-2Manα-[GlcNAc1ß-2Manα-6]-3Man) (Figure 31A) 
were reported in 2001 [188]. The pentasaccharide contains a central mannose linked 
through the 3- and 6-positions to the disaccharide GlcNAc1ß-2Man1α. Whereas the 
DC-SIGN-carbohydrate complex contains a pair of CRDs bound to one 
oligosaccharide, the DC-SIGNR complex reveals a 1:1 CRD-oligosaccharide 
interaction (Figure 32). In the DC-SIGN complex, one CRD forms the same contacts 
to four sugar residues as observed in the DC-SIGNR structure, but the fifth sugar 
residue (terminal GlcNAc) interacts with the partner CRD in the DC-SIGN complex. 
The conformation of the pentasaccharide is essentially identical in both structures. 
The internal α−1,2-linked mannose binds to the Ca2+ site found on all C-type lectins, 
with the equatorial 3- and 4-hydroxyls coordinating with the Ca2+ ion (Figure 32). 
The oligosaccharide also makes several hydrophobic and hydrogen-bonding 
interactions with the rather flat ligand-binding site on each receptor protein. The 
crystal structures reveal the strong preference for binding N-linked glycans where the 
central mannose is linked in the α-form, a structural motif only found in high-
mannose oligosaccharides. 
 Further insights into the ability of DC-SIGN to bind fucosylated ligands came 
from a crystal structure of DC-SIGN bound to the pentasaccharide lacto-N-
fucopentaose-III (LNFP-III), which contains the Lewisx trisaccharide (Figure 33) 
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[189]. The conserved Ca2+ at the primary carbohydrate-binding site is coordinated to 
the 3- and 4-hydroxyls of the α1,3-linked L-fucose residue in LNFP-III (Figure 34A). 
However, since these hydroxyls are equatorial and axial, respectively, rather than both 
being equatorial as seen in bound mannose (Figures 32), the fucose sugar is tilted. 
The compact structure of the Lewisx trisaccharide is oriented with the central GlcNAc 
residue in LNFP-III pointing away from the protein and the terminal galactose residue 
contacting the protein in a secondary binding site. Various van der Waals as well as 
hydrogen bonding interactions are seen between the bound ligand and the receptor. 
The structure suggests that other fucose-containing ligands may bind with fucose in 
the primary (principal Ca2+) binding site. 
 A crystal structure was also reported of a DC-SIGNR fragment bound to the 
simple Lewisx trisaccharide [189], although this ligand has only weak affinity for DC-
SIGNR (≈ mM). The position of the bound ligand is very similar to the position of the 
corresponding portion of the LNFP-III ligand bound to DC-SIGN. However, several 
key differences in ligand-protein contacts are also seen between the two complexes 
(Figure 34B). A third crystal structure comprises a complex of the CRD of DC-SIGN 
bound to a branched tetra-mannose (Man4) (Figure 33) [189]. The α-linked terminal 
reducing mannose residue is accommodated because it points away from the protein, 
indicating why binding of branched high mannose oligosaccharides is permitted by 
DC-SIGN. 
 Further insights into binding of branched mannose carbohydrates to DC-SIGN 
came from crystal structures of its CRD bound to a hexa-mannose fragment (Man6, 
Figure 33) of the full N-linked high mannose oligosaccharide (Man9GlcNAc2), as 
well as to the disaccharide Manα1-2Man (Table 1) [190]. These structures revealed 
the carbohydrate ligands occupying two different overlapping orientations in the 
crystal, in a ratio ≈75:25. The major orientation seen with the hexamer corresponds to 
the arrangement seen in earlier crystal structures [189], but the α1-6 branch of the 
carbohydrate is not visible. The penultimate α1-3-linked mannose that forms one arm 
of the outer-branched trimannose unit interacts with the primary Ca2+ site. In the 
second (minor) orientation, the same mannose is bound to Ca2+, but its orientation is 
reversed by a 180o rotation. This rotation exchanges the position of the 3- and 4-OH 
groups so that they can still coordinate to Ca2+. In this orientation only two sugars are 
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visible in the complex; the mannose at the Ca2+ site and the non-reducing terminal 
α1-2-linked mannose. In the complex with the disaccharide Manα1-2Man, binding is 
only seen at the principal Ca2+ site; no other binding site was occupied on the protein. 
However, the ligand again binds in two orientations, related by a 180o rotation that 
interchanges the positions of the 3- and 4-OH groups coordinated to Ca2+.  
 These observations show that high mannose oligosaccharides can interact with 
DC-SIGN in multiple orientations, with the primary energetic interaction occurring at 
the primary Ca2+ site, but with multiple secondary interactions occurring through 
neighboring binding sites. The ability of DC-SIGN (and DC-SIGNR) to bind high 
mannose glycans in multiple orientations may facilitate multivalent binding of 
clusters of CRDs to glycans displayed in various arrangements on the surface of a 
pathogen. The CRDs of DC-SIGN and DC-SIGNR bind Man9GlcNAc2 
oligosaccharide 130- and 17-fold more tightly than mannose (mannose affinity is 
weak - in the mM range), and the affinity for a glycopeptide bearing two such 
oligosaccharides is increased a factor of 5- to 25-fold [191]. Moreover, closer spacing 
of the two oligosaccharides causes a greater increase in affinity to DC-SIGNR than to 
DC-SIGN, suggesting that the spacing of high mannose N-linked oligosaccharides on 
a protein surface influences significantly the selectivity of ligand recognition. 
 Langerin is another type-II transmembrane PRR found on Langerhans cells. 
The ECD comprises a neck region that forms trimeric helical bundles, linked to a 
CRD at the C-terminus. The CRD binds various monosaccharides in a calcium-
dependent manner, including mannose, fucose and N-acetylglucosamine, as well as 
oligosaccharides like mannan [192]. Binding of the monomeric CRD to 
monosaccharides is weak (≈mM range). However, oligomerization again facilitates 
multivalent, higher-affinity binding to oligosaccharides. A role for langerin has been 
proposed in internalization of both self and non-self glycoprotein antigens. Crystal 
structures show how the CRD from langerin interacts with mannose and the 
disaccharide maltose (Table 1) [193]. In both structures, an important determinant of 
monosaccharide recognition is coordination through the pyranose equatorial 3- and 4-
OH groups to Ca2+ in the primary Ca2+ site. 
 
3.2. Mannose-binding lectins 
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Mannose is found in an extensively branched multivalent format only on the 
surface of microorganisms. It is not surprising, therefore, that the innate immune 
system has developed mechanisms for recognizing this form of mannose as a PAMP. 
However, mannose is also found in many human glycoproteins at non-terminal sites 
and at a much lower surface density. A key role in innate defense is played by cell 
surface membrane proteins, such as the mannose receptor, which mediates 
phagocytosis of microorganisms by macrophages and DCs. In addition, soluble 
mannose-binding lectins in the circulation are greatly up-regulated during infections, 
and upon binding to terminal mannose on the bacterial surface, initiate antibody-
independent complement activation. 
 The mannose receptor (MR) belongs to a small subgroup of the C-type lectin 
superfamily, which also includes DEC-205, Endo180 and PLA2R [25, 29, 34, 194]. 
The MR binds carbohydrate moieties on pathogens, such as bacteria, fungi, parasites, 
and viruses. However, the MR also binds endogenous glycosylated molecules, in 
particular, pituitary hormones such as luteinizing hormone and thyroid-stimulating 
hormone, influencing their circulatory half-life. Thus, the MR has multiple roles apart 
from its functions in the immune system [27, 36, 195]. The MR is preferentially 
expressed on DCs, tissue macrophages, and specialized endothelial cells, and 
constitutively recycles between the plasma membrane and the early endosomal 
compartment.  
 The MR has an unusual topology, with the N-terminus outside the cell, a 
single transmembrane segment and a short C-terminal cytoplasmic domain [34]. The 
ectodomain contains a cysteine-rich domain at the N-terminus, followed by a 
fibronectin type-II (FNII) domain and then a series of eight C-type lectin domains 
(CTLDs 1-8) leading down to the cell membrane (Figure 35). The Cys-rich domain 
binds to a variety of sulfated carbohydrates, including glycoproteins and hormones 
terminating in sulfated N-acetylgalactosamine, 3-sulfated galactose and fucose, as 
well as chondroitin-4-sulfates. The function of the FNII-domain is so far unclear, but 
the domain is predicted to adopt the canonical fold seen in other FNII domains. The 
MR displays Ca2+-dependent binding to terminal mannose, fucose and N-
acetylglucosamine residues. Only CTLD4 shows significant carbohydrate binding as 
an isolated domain, although CTLD5 retains weak sugar binding activity, which is 
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consistent with the observation that only CTLD4 and CTLD5 contain the conserved 
residues required for Ca2+-dependent carbohydrate recognition [34]. 
 Soluble mannose-binding proteins (MBPs) recognizes a wide variety of 
branched microbial carbohydrates present on the surface of yeasts, bacteria, 
mycobacteria, and some viruses such as influenza and HIV-1 [35]. Human MBP is a 
multimeric protein consisting of a ≈32 kDa subunit, which associates into trimers and 
then into higher multimers in a "bouquet-like" array (Figure 35). Each subunit 
contains an N-terminal cysteine-rich domain, followed by a collagen-repeat region, a 
neck region comprising a coiled-coil motif, and finally a CRD exposed on the outer 
surface of the bouquet that requires calcium to bind ligand. The coiled-coil mediates 
formation of a trimeric parallel α-helical bundle, and the resulting trimers then 
assemble further into higher multimers, likely through association of their collagen-
like domains (Figure 35). The affinities of the isolated CRDs for monosaccharides are 
relatively low (mM range), however, the apparent affinity of the multimeric MBP for 
branched multivalent ligands is dramatically higher (nM) [196]. On the other hand, 
assemblies of lower valency, such as linear carbohydrate chains found on host 
glycoproteins, interact with MBPs with much lower affinity [197]. Crystal structures 
proved to be important for understanding how MBP can distinguish between host and 
pathogen-derived mannosylated ligands, as described below. 
 
3.2.1. Mannose-binding proteins  
The crystal structures of rat and human MBP fragments, comprising the CRD 
and the coiled-coil neck domain, revealed how MBP trimers form the basic 
recognition unit for branched oligosaccharides on microorganisms (Figure 36) [198, 
199]. The neck region incorporated into both constructs was 24-30 residues long, 
which as isolated peptides show no regular secondary structure. In the context of the 
MBP fragment, this neck region adopts a parallel trimeric helical bundle, with 
hydrophobic residues at the a/d positions of a heptad repeat. The presence of the CRD 
domain in each chain stabilizes the trimeric structure through direct contacts with 
neighboring chains. This packing arrangement gives each CRD a well-defined 
orientation, and determines the relative spatial organisation of the carbohydrate 
binding sites, which are located about ≈50Å from each other. This relatively large 
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distance makes it difficult for a single mammalian high-mannose oligosaccharide 
chain to interact with more than one CRD within the trimer. However, since the 
carbohydrate binding sites all point out from the same side of the molecule, they are 
ideally positioned to interact with dense sugar arrays on a microbial cell surface. 
Within each CRD, bound Ca2+ ions are important for the interaction with 
carbohydrate ligands. The primary Ca2+ ion interacts with ligand by coordinating to 
the 3- and 4-hydroxyls in bound mannose, as revealed in a crystal structure of rat 
mannose-binding protein A (MBP-A) complexed with a branched oligomannose 
sugar (Table 1) [200]. Only the terminal mannose of each visible branch of the 
oligosaccharide interacts with the CRD; the rest of the carbohydrate points away from 
the CRD and makes limited contacts with the protein. Further crystal structures of 
MBP-A and MBP-C have been reported with various bound monosaccharides (e.g. 
mannose, N-acetylglucosamine, and fucose) and disaccharides, as well as the MBP-A 
trimer cross-linked by a high mannose oligosaccharide (Table 1) [201, 202]. The 
structures reveal that the monosaccharides or α1-6-linked mannose can bind to MBP-
A in one orientation, whereas α1-2- or α1-3-linked mannose binds in an orientation 
rotated by 180o around an axis relating the 3- and 4-OH groups. In contrast, a similar 
set of ligands all bind to MBP-C in a single orientation. Each MBP seems to interact 
with a particular ligand in preferably one orientation. The protein residues that serve 
as both Ca2+ and sugar ligands are the same in both MBP-A and MBP-C. However, 
one residue close to the binding site (His 189 in MBP-A) appeared by mutagenesis to 
have a key influence upon the orientation of bound ligands in MBPs [202-204]. 
Finally, the crystal structure of MBP-A trimer bound to Man6GlcNAc2Asn revealed 
the two trimers cross-linked by the oligosaccharide (Table 1) [202]. The trimers are 
arranged in hexagonal packed sheets in the crystal with the sheets cross-lined by the 
oligosaccharide. It was suggested that this packing arrangement might indicate how a 
cell surface presenting mannose-terminated sugars (one layer of the crystal) could be 
recognized by a multimeric form of MBP-A (represented by the opposing layer). 
 
3.2.2. The mannose receptor 
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 The crystal structure of CTLD4 from the MR (Figure 35) was reported in 2000, 
although the structure does not contain bound carbohydrate ligand [205]. The overall 
structure of the CTLD4 domain is similar to that of other C-type CRDs (Figure 37A). 
Equivalent residues in this domain can be superimposed on those from MBP-A with 
an rmsd of 0.15 nm. Unlike the core of the domain, where the similarity is greatest, 
striking differences are seen in the size and structure of some surface loops.  A rather 
large, extended and flexible loop that follows the ß2 strand is seen in CTLD4 
(residues 701-734), which is absent in MBP-A. This region is stabilized in MBP-A by 
two bound Ca2+ ions, including the principal Ca2+ site that interacts with bound 
mannose. In the CTLD4 structure, however, only the primary site located close to the 
base of the extended loop is occupied with bound Ca2+. Attempts to induce ligand 
binding by soaking crystals in high concentrations of sugar failed to reveal a binding 
site. It seems, therefore, that the structure present in the crystals is unable to bind the 
full complement of Ca2+ nor mannose ligands. It was speculated that the structure 
may be related to an intermediate that must occur physiologically in endosomes, 
where the slightly acidic pH could lead to loss of Ca2+ and de-binding of sugar ligands. 
The ligand and receptor then sort from one another, with the receptor returning to the 
cell surface for another round of ligand binding. Indeed, isolated MR CTLD4 displays 
reversible, pH-dependent Ca2+ and sugar binding, with a mid-point in the transition 
around pH 5.0. 
 Crystal structures have also been reported of the cysteine-rich N-terminal 
domain of the MR, which plays a critical role in binding sulfated glycoproteins, 
including pituitary hormones [206, 207]. This globular domain of ≈130 residues 
adopts a ß-trefoil, possessing 12 anti-parallel ß-strands with six forming an almost ß-
barrel like arrangement, with the entire trefoil stabilized by three disulfide bonds 
(Figure 38A). The structure of this domain bears no resemblance to the CRDs found 
in the MR and other CTLDs. The ligand, 4-sulfated N-acetylgalactosamine (GalNAc-
4-SO4) binds with a KD ≈0.1mM with its sulfate group inserted into a binding pocket 
formed on one side by residues 111-116 in the loop between strands 11 and 12, and 
the other side by the side chains of Asn102 and Trp117, and on the bottom by the Asn99 
side chain (Figure 38B). The sulfate group makes extensive hydrogen bonding and 
van der Waals contacts to the protein. The galactose ring is positioned with the polar 
A-face exposed to solvent and the non-polar B-face stacked against the indole of 
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Trp117. This stacking arrangement is also seen in several other protein-galactose 
complexes [206]. The sulfate group does not interact with positively charged side 
chains or counter ions. Rather, the interactions with the protein are mediated through 
multiple hydrogen bonds involving peptide bond NH groups. This domain binds to 
GalNAc or galactose when it is sulfated at the C3 or C4 positions, and more weakly if 
the sulfate is at C6. The lack of discrimination between sugars with and without the 
N-acetyl group is explained by the absence of any direct contact between the NAc 
group and the protein. The protein recognizes sulfated GalNAc when it is terminal but 
not internal within an oligosaccharide chain, which again can be nicely explained by 
the crystal structure. Another sugar residue linked to C3 would prevent access of the 
sulfate group to the binding pocket. The anomeric center of the bound ligand points 
away from the protein surface, thus allowing attachment of another sugar at this 
position without causing steric hindrance. 
 Crystal structures and affinities of 3-SO4-Lewisx, 3-SO4-Lewisa and 6-SO4-N-
acetylglucosamine bound to the Cys rich domain have also been reported [207]. The 
conformation of the protein is virtually identical in all crystal structures. Interestingly, 
a 6-SO4-Gal binds with KD ≈1 mM, whereas 6-PO4-Gal showed no detectable binding 
to the Cys-rich domain, suggesting that the slightly larger phosphate group is not 
accommodated within the sulfate-binding site. 
 
4.  Structures of NOD-like receptors 
 Relatively few structural studies at atomic resolution have been reported on 
NLRs to date, nor how they recognize specific PAMPs. The crystal structure of a 
fragment derived from NLRX1 has been reported, but not bound to its RNA ligand. 
 
4.1. RNA-Binding domain of NLRX1 
NLRX1 (also known as NOD9) is a proinflammatory activator that localizes to 
mitochondria, and stimulates the production of reactive oxygen species via TNFα 
activation [208]. However, this receptor has a more complex immune modulatory 
function, since it can also down-regulate inflammatory responses as a negative 
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regulator of RIG-1 and TLRs through interaction with mitochondrial signaling 
adaptors [209, 210]. Recently a crystal structure was reported of the C-terminal 
fragment of human NLRX1 (called cNLRX1, residues 629-975), along with evidence 
that this receptor interacts specifically with an RNA ligand [59]. 
 The cNLRX1 protein contains the entire C-terminal putative ligand-binding 
domain comprising eight LRRs as well as an N-terminal two-helix domain (LRR-NT) 
and a C-terminal antiparallel three-helix bundle (LRR-CT) (Figure 39) [59]. The 
central domain with eight LRR modules folds into a crescent-shape with the parallel 
ß-strands oriented on the concave side. The LRR1-LRR7 motifs have the typical LRR 
fold, except LRR8, which does not contain an α-helix on the convex side, but rather 
proceeds directly into the LRR-CT domain. The concave face encircles and docks 
onto one side of the LRR-CT domain. The cNLRX1 protein elutes in two fractions 
from a gel filtration column, with apparent masses corresponding to monomer (≈39 
kDa) and hexamer (≈240 kDa). In the crystal structure, the protein assembles into a 
hexamer with 2-fold crystallographic symmetry and 3-fold non-crystallographic 
symmetry. Three cNLRX1 chains associate by intertwining of helical segments of 
their LRR-NT domains at the center to create the 3-fold axis. Two trimeric subunits 
then assemble into a hexamer, with the LRR-CT domains buried at the interface 
(Figure 39). The LRR-CT domain plays a key role in dimerization and provides 
structural support for the LRR modules through intra-subunit and inter-subunit 
interactions. 
 Potential ligands for cNLRX1 have been probed by electrophoretic band shift 
assays [59]. In this way, binding to ssRNA and dsRNA was detected with binding 
affinities around 1µM and 0.1µM, respectively. However, no binding was observed to 
ssDNA or dsDNA. A possible binding site for the RNA was identified around a large 
surface exposed patch of positively charged Arg and Lys residues, which lies on one 
face of each monomer. Mutation of a key arginine within this region, Arg699, inhibits 
RNA binding. A model was also proposed for the full-length NLRX1 hexamer, in 
which NOD-NAD domains extend from the LRR domain and decorate the exterior 
surface of the hexamer [59]. The NOD domains might further mediate 
oligomerization into ring-like assemblies, as well as mediating binding to other 
interacting partners. 
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4.2. Pyrin domains and CARDs  
NLRs containing an N-terminal pyrin domain (PYD) or a caspase activation and 
recruitment domain (CARD) form the largest group of NLRs (NLRPs), with 14 
members in humans (NLRP1-14) [38, 40, 41, 48, 50]. For example, NLRP1 and 3 
activate the inflammatory immune response by detecting cytosolic PAMPs via their 
C-terminal LRR domains. Once activated, NLRP1 and 3 oligomerize via their central 
NACHT domains. Finally, the N-terminal PYDs recruit the ASC adaptor protein, and 
then pro-caspase 1 molecules. The resulting multicomponent signaling complex, 
termed the inflammasome [48], results in autoproteolytic activation of caspase 1, 
which in turn cleaves proinflammatory cytokines such as pro-IL1ß and pro-IL18 into 
their mature forms [47]. 
 Several PYD structures have been determined recently, by crystallography or 
NMR spectroscopy, including from NLRP3 (also called NALP3) [211], NLRP1 (or 
NALP1) [212], the ASC adapter protein [213, 214], NLRP12 [215], NLRP7 [216], 
ASC2 [217], and NLRP4 [218]. These structures reveal a high degree of conservation 
with a fold comprising a six-helix bundle. The structures of several CARDs 
determined by crystallography or NMR spectroscopy have also been reported [214, 
219-222]. These domains also adopt a compact 6-helix bundle structure in crystals 
and in solution. 
 
5.  Structures of RIG-like receptors (RLRs) 
  
 The RLRs are multi-domain proteins (Figure 4). RIG-I and MDA5 share a 
similar domain organization, comprising tandem N-terminal CARD domains, 
followed by a domain that belongs to the DExD/H-box helicase superfamily, followed 
by a small regulatory domain and a C-terminal RNA-binding domain (CTD) [64]. 
Helicases comprise a large superfamily of enzymes. They are nucleic acid-dependent 
ATPases that promote unwinding of dsDNA or dsRNA, and are therefore involved in 
many important cellular processes [223]. Helicase domains convert chemical to 
mechanical energy by coupling ATP binding and hydrolysis to protein conformational 
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changes. In contrast to bona fide helicases, however, RIG-I translocates on dsRNA 
and recognizes the 5'-PPP motif, which leads to large conformational changes and 
RIG-I activation. Recent structural studies have shown that activation of RIG-I occurs 
through an RNA- and ATP-driven structural switch in the helicase domain, which 
exposes CARDs that then mediate downstream signaling [224]. This likely occurs 
through dsRNA binding to the helicase domain, resulting in activation of the ATP-
hydrolyzing function and a conformational change of the complex that exposes the 
CARDs. The CARDs then transmit signals downstream by recruitment of other 
molecules, which leads finally to the expression of antiviral interferon-stimulated 
genes [225-227]. LPG2 has a similar domain organization, except that it lacks the 
CARD homology region. 
 Recent structural studies of RLRs (reviewed recently [228]) have provided 
important insights into the structural basis for dsRNA and 5'-PPP-RNA sensing by 
these receptors. 
 
5.1. RNA recognition by RIG-I 
A thermodynamic analysis revealed that blunt ended 5'-PPP dsRNA is required for 
maximal binding affinity to RIG-I [229], and the CTD provides the greatest 
thermodynamic contribution to binding. The helicase domain, on the other hand, 
plays a key role in specific binding to dsRNA, rather than ssRNA. In 2008, 
crystallographic and NMR studies provided the first atomic models of the CTD 
domain of RIG-I [230, 231]. These results were followed by crystal structures of the 
RIG-I CTD bound to the blunt ends of a synthetic 5'-triphosphorylated dsRNA 
oligonucleotide. Interactions involving the 5'-PPP group were clearly visible in the 
complex, sequestered in a basic lysine rich patch on the protein surface (Figure 40) 
[232, 233]. The side chain of Phe853 stacks over both bases of the terminal base pair 
of the dsRNA in the complex, consistent with the requirement for a blunt-end duplex. 
Later, additional crystal structures were reported of larger fragments of RIG-I, also 
with bound nucleotide analogues, including ADP or ADP-AlF3 (a mimic of the 
transition state of ATP hydrolysis) or ADP-BeF3 (likely an ATP structural mimic), 
and bound 5'-triphosphorylated RNA [234-238]. These results provided key insights 
into the likely mechanism of RNA- and ATP-dependent receptor activation. 
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 Pyle and coworkers reported crystal structures of human RIG-I in complex 
with dsRNA (lacking a 5'-PPP) and in a complex with a 5'-triphosphorylated RNA 
hairpin and ADP (Figure 41) [237, 238]. This RIG-I protein lacked the N-terminal 
CARD domain (res. 1-229) and was co-crystallized first with blunt-ended duplex 
RNA. The RIG-I protein in the crystal completely surrounds the bound RNA and 
encloses it within an elaborate network of mostly polar interactions (Figure 41). 
Numerous contacts are formed between 2'-hydroxyl groups on the RNA and protein 
amide groups. Helicase domain 1 (HEL1) faces the minor groove of the RNA and 
interacts with the backbone of both RNA strands. Almost half of the HEL2 domain is 
disordered in the structure, perhaps due to the absence of the CARD domains and/or 
ATP. An insertion domain (HEL2i) within HEL2, comprising an α-helical bundle, is 
a component of the ring that grips the dsRNA by interaction with the minor groove. 
HEL2i plays an important role in the specific recognition of RNA. Strikingly, HEL2 
and the CTD are connected through a V-shaped structure (also called a pincer (P) 
motif [236]) composed of two long α-helices that make a 65o turn (Figure 41), which 
establishes extensive interactions between HEL1, HEL2 and the CTD. Although the 
pincer is not part of the ATPase site, nor is it a direct RNA-binding site, it likely 
transmits information essential for RNA sensing between these sites. The CTD 
interacts with the RNA in a manner similar to that seen in previously reported CTD 
structures. The Phe853 side chain again stacks over the terminal base pair in the RNA. 
The dsRNA adopts an A form conformation, with no evidence of destabilization or 
partial unwinding. The RNA-binding interface involves at least three separate 
domains. RIG-I undergoes large ATP-driven conformational changes upon binding to 
dsRNA, with the dsRNA providing a template for RIG-I domain assembly [234]. 
 The crystal structure of RIG-I(∆-CARD) bound to a designed RNA hairpin 
containing a 5'-PPP and ADP is similar to the RIG-I:dsRNA structure described 
above (Figure 42A) [238]. The RNA contains a 5'-triphosphate and a stem of 8 bp that 
is linked by a UUCG tetra-loop, an arrangement that mimics the panhandle-like 
structures formed by the genomes of many negative-stranded RNA viruses. The 
structure is likely to be biologically relevant since the RNA stimulates efficient ATP 
hydrolysis by RIG-I. The CTD now encapsulates the 5'-PPP at the duplex terminus 
through a network of electrostatic interactions involving K861, K888, K858 and H847 
(Figure 42B). The α and ß phosphates at the 5' terminus are particularly critical for 
 53 
RIG-I binding, which together with the favorable π-π stacking of F853 side chain onto 
the terminal base pair, helps RIG-I to select the correct pathogenic RNA from the vast 
pool of capped cellular RNAs. The γ-phosphate does not form direct contacts with the 
protein, suggesting that it is not a major recognition determinant. The position of the 
bound nucleotide (ADP) was identified within conserved ATPase motifs in HEL1. 
HEL2 is not involved in RNA or ADP binding, however, the HEL2i domain again 
makes an extensive contact interface with the RNA duplex. The UUCG tetra-loop at 
the other hairpin terminus is absorbed into an RNA-binding funnel and does not 
establish any base-specific contacts with RIG-I. The phosphates of ADP are bound to 
RIG-I through a bridging Mg2+. 
 A comparison of available RIG-I:nucleotide structures indicates that the 
helicase domain is in an open conformation in the absence of RNA substrate [235-
237]. In the presence of RNA and the ATP analogue ADP-AlF3, the helicase domain 
adopts a closed conformation (Figure 43). In the complex with ADP-Mg2+, the 
product of ATP hydrolysis, RIG-I adopts an intermediate semi-closed state. The RIG-
I conformation thus appears to be very sensitive to ATP binding, hydrolysis, and 
product release. This leads to a model for RIG-I signaling, where after RNA binding, 
ATP hydrolysis moves the CTD and HEL2i domains in opposite directions, which 
likely allows the CARDs to be released from HEL2i into a position where they can 
signal to downstream molecules (Figure 43) [238]. 
 
5.2. RNA recognition by MDA5 
MDA5 is a second cytoplasmic viral RNA receptor, which shares high sequence 
similarity to RIG-I, and interacts with a common signaling adapter MAVS, which 
activates interferon signaling pathways [239]. However, these sensors recognize 
largely distinct groups of viruses and viral RNAs. MDA5 detects long-duplex RNAs 
in the genome of dsRNA viruses or dsRNA replication intermediates of positive 
strand viruses. Nevertheless, MDA5 and RIG-I have similar domain architectures, 
with N-terminal CARD domains that interact with MAVS, a central helicase domain 
for RNA-dependent ATP hydrolysis, and a C-terminal domain (CTD) (Figure 4). 
However, the CTD of MDA5 displays affinity for dsRNA that is orders of magnitude 
 54 
lower than that of full length MDA5, suggesting different mechanisms of dsRNA 
recognition by RIG-I and MDA5 [240]. 
 MDA5 forms a higher-order structure during RNA recognition and signaling, 
by cooperatively assembling into a filamentous oligomer composed of a repeating 
segmental arrangement of MDA5 dimers along the length of dsRNA [240]. Binding 
of MDA5 to dsRNA stimulates ATP hydrolysis, which stimulates assembly and 
disassociation of MDA5 from dsRNA in a manner inversely proportional to the 
filament length. Thus, ATP hydrolysis has a key role in the control of filament 
assembly and disassembly, thereby autoregulating the interaction of MDA5 with 
dsRNA, and likely providing a basis for dsRNA length-dependent antiviral signaling. 
 Recently, a crystal structure was reported of human MDA5 lacking the CARD 
domains (res. 298-1018), an internal loop (res. 645-662) and the C-terminal tail 
(1018-1025) [241]. These deletions do not affect RNA-binding affinity or ATP 
hydrolysis activity of the MDA5, but afforded crystals of the protein (MDA5∆N') 
complexed to a 12 bp dsRNA and an ATP analog (5'-adenyl-ß-imidodiphosphate 
(ADPNP)). 
 The structure of the ternary complex reveals that MDA5∆N' forms a ring-like 
structure around the 12 bp dsRNA (Figure 44). MDA5 makes contact with the dsRNA 
using the HEL1, Hel2i, Hel2 and CTD domains, but not the pincer (P) domain. Most 
protein residues interact primarily with the RNA phosphate backbone and 2'-hydroxyl 
groups, consistent with sequence-independent recognition of dsRNA. Mutational 
studies suggest that all domains make important contributions to high affinity dsRNA 
recognition [241]. Similar interactions are found upon RNA binding to RIG-I, with 
the exception of interactions involving the CTD. The bound ADPNP is located in a 
cleft between HEL1 and HEL2, in the outer rim of the MDA5 ring structure. A 
structurally similar binding site for the nucleotide is found in RIG-I. 
 A major difference between MDA5 and RIG-I is seen in the orientation of the 
CTD [241]. Whereas in RIG-I the CTD encapsulates the 5'-PPP end of the RNA, in 
the complex with MDA5 the CTD (res. 900-1017) is oriented differently so that it 
makes contact to the side of the dsRNA (Figure 45). This difference in CTD 
orientation results in an open, C-ring-shaped structure of MDA5 that binds to the stem 
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of dsRNA, as opposed to the O-ring structure formed by RIG-I, which caps the 
dsRNA end. On the other hand, the conformation of the helicase domain is well 
preserved between RIG-I and MDA5 (Cα RMSD 1.9 Å). In both complexes with 
RNA, the CTDs form an extensive interaction with HEL2i, with buried surface areas 
of ≈510Å2. The convex surface of the Zn-binding site in the CTD is complementary 
to the concave face of HEL2i. Interestingly, a surface loop in HEL2 (res. 758-767) of 
MDA5 inserts into the major groove of the bound dsRNA stem, whereas in RIG-I the 
equivalent loop binds to the end of the RNA (Figure 45). In the MDA5-dsRNA 
complex, the major groove is widened from 1.2 nm to 1.8 nm at the site of the HEL2 
loop insertion, but the interaction between the inserted loop and dsRNA is limited to 
the phosphate backbone and does not lead to sequence-dependent base recognition. A 
∆HEL2-loop mutant, however, still bound strongly to dsRNA, but lacked the dsRNA-
dependent ATP hydrolysis activity. Thus, insertion of the HEL2 loop into the major 
groove seems to be important for ATP hydrolysis and subsequent signaling. Overall, 
close interaction between the helicase domain and the CTD provides the molecular 
basis for the divergent RNA specificity of MDA5 and RIG-I. 
 EM studies have revealed that MDA5 rings bind and stack along dsRNA to 
form filamentous oligomers [240, 242, 243]. Structural models of the filaments have 
been built using both EM and crystallographic results. High-resolution structural 
models predict a head-to-tail association of MDA5 subunits in the filaments, a 
repeating unit of ≈14 bp, and a turn of ≈70o between each monomer (Figure 46) [241]. 
This arrangement leads to a monomer-monomer interface comprising largely the 
helicase domain, with a total buried surface area of ≈1500 Å2. Defining the complete 
architecture of full-length MDA5, however, requires knowledge of the arrangement of 
the two CARDs within the filament. Biochemical studies have shown that isolated 
2CARDs can self-oligomerize at high protein concentration. This oligomerization of 
the CARDS is required to activate the downstream signaling molecule MAVS. 
Favored models of full length MDA5 within filaments bring the 2CARD from each 
monomer together to form discrete filaments or patches of oligomers along the central 
MAD5 filament (Figure 46) [241]. The size, frequency and positioning of individual 
patches are stochastically determined during MDA5 filament assembly and ATP 
hydrolysis. Thus, MDA5 binding to dsRNA, filament formation, and additional 
conformational rearrangements during ATP hydrolysis, appear to be required for 
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efficient oligomerization of the CARDs and interaction with MAVS. ATP hydrolysis 
does not simply trigger assembly or disassembly of the filament, but is required to 
allow 2CARD oligomerization and binding to MAVS. 
 
Note added in proof 
A recent study describes the crystal structure of a fragment derived form mouse 
NLRC4 [244]. The NLRC4 inflammasome is activated in mice by bacterial flagellin 
or the components of type 3 secretion system. In another study, the crystal structure 
was reported of a RIG-I:dsRNA complex. A minimal RNA duplex was identified that 
binds one RIG-I molecule, stimulates robust ATPase activity, and elicits a RIG-I-
mediated interferon (IFN) response in cells [245]. Other studies establish a clear role 
for the ligand-induced ATPase activity of RIG-I in the stimulation of an IFN response 
[246]. 
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Table 1. Structures of Pattern Recognition Receptors and complexes with PAMPs 
available in the protein database (PDB). 
 
PRR Source  
 
Resol. 
(x10 
nm) 
PDB code Reference 
TLR1/2 
 
 
human TLR1-
TLR2+Pam3CSK4 complex 
 
mouse TLR2 dimer with 
Pam3CSK4 or Pam2CSK4 
2.10 
 
 
1.80 
2.60 
2Z7X 
 
 
2Z81 
2Z82 
[74] 
 
 
[74] 
 
TLR2 mouse TLR2 with PE-DPTA or       
pn-LTA 
2.4 
2.5 
3A76 
3A7B 
[75] 
TLR2/6 mouse TLR2-TLR6 + 
Pam2CSK4   
2.9 3A79 [75] 
CD14 mouse CD14  
human CD14 
2.5 
4.0 
1WWL 
4GLP 
[128] 
[127] 
TLR3 human TLR3  
 
 
mouse TLR3 alone 
and with dsRNA 
2.4 
2.1 
 
2.66 
3.41 
2A0Z 
1ZIW 
 
3CIG 
3CIY 
[78] 
[77] 
 
[80] 
MD2 
 
 
TLR4/MD-2 
 
 
 
 
 
human MD-2 alone 
and with lipid IVa 
 
mouse TLR4 with MD-2 and 
bound endotoxin 
 
human TLR4 with MD-2 and 
bound LPS 
 
mouse TLR4/MD-2 with  
lipid-IVa 
with LPS 
 
2.00 
2.21 
 
 
2.84 
 
 
3.10 
 
 
2.70 
2.48 
2E56 
2E59 
 
 
2Z64 
 
 
3FXI 
 
 
3VQ1 
3VQ2 
[143] 
 
 
 
[102] 
 
 
[144] 
 
 
[148] 
FliC 
 
TLR5 
Salmonella sp. flagellin 
 
Zebra fish TLR5 
TLR5 with flagellin 
2.00 
 
2.83 
2.47 
1IO1 
 
3V44 
3V47 
[149] 
 
[83] 
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TLR8 human TLR8, unliganded 
 
hTLR8 with CL097 
hTLR8 with CL075 
hTLR8 with R848,  
3 forms 
2.30 
 
2.00 
2.30 
2.33  
2.70 
2.10 
3W3G 
 
3W3J 
3W3K 
3W3L 
3W3M 
3W3N 
[160] 
 
[160] 
DC-SIGN 
DC-SIGNR 
human DC-SIGN and DC-
SIGNR CRD with bound sugar 
5mer 
 
DC-SIGN+ Man4 
DC-SIGN+LNFP-III 
DC-SIGN+Lewisx 
 
DC-SIGN+Man6 
DC-SIGN+Man2 
 
DC-SIGNR neck region 
 
DC-SIGNR neck region 
 
2.50  
1.90  
 
 
1.55 
1.80 
2.25 
 
2.40 
1.95 
 
2.25 
1.41 
2.20 
 
1K9I  
1K9J 
 
 
1SL4 
1SL5 
1SL6 
 
2IT5 
2IT6 
 
1XAR 
1XPH 
3JQH 
 
[188] 
 
 
 
[189] 
 
 
 
[190] 
 
 
[185] 
[186] 
[187] 
 
Langerin apo-human Langerin 
Langerin + disaccharide 
Langerin+ mannose 
2.50 
2.30 
1.50 
3P7F 
3P7H 
3P7G 
[193] 
Mannose 
binding 
proteins 
(lectins) 
rat MBL CRD+neck 
hMBL CRD+neck 
rat MBP CRD 
rat MBP-A+mannose 
rat MBP-A CRD 
rat MBP-C+sugars 
 
 
 
 
 
 
MBP-A+galactose 
 
 
MBP-A+Lewisx oligos 
 
 
 
rat MBP-C 
 
rat MBP-C+GalNAc 
 
rat MBP-A 
1.80 
2.50 
2.30 
1.70 
1.80 
1.70 
1.80 
1.90 
1.70 
1.80 
1.80 
1.80 
2.00 
1.90 
2.00 
2.10 
2.00 
1.95 
2.00 
1.85 
1.90 
2.10 
2.00 
1.95 
1RTM 
1HUP 
1MSB 
2MSB 
1YTT 
1RDO 
1RDN 
1RDM 
1RDL 
1RDK 
1RDJ 
1RDI 
1AFA 
1AFB 
1AFD 
1KMB 
2KMB 
3KMB 
4KMB 
1BV4 
1BUU 
1BCJ 
1BCH 
1KWT 
[199] 
[198] 
[248] 
[200] 
[249] 
[201] 
 
 
 
 
 
 
[204] 
 
 
[250] 
 
 
 
[251, 252] 
 
[203] 
 
[202] 
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+αMe-O-Man 
+αMe-O-GlcNAc 
+αMe-O-Fuc 
+ßMe-O-Fuc 
+Manα1-3Man 
H189V+ Manα1-3Man 
H189V/I207V+ Manα1-3Man 
+Man6GlcNAc2Asn 
rat MBP-C+Manα1-3Man 
+Manα1-3[Manα1-6]Man 
+Manα1-2Manα1-6Man 
+GlcNAcß1-2Manα1-
3[GlcNAcß1-2Manα1-6]-Man 
+N-Ac-Tyr-Asp-[Gly-Gly-NH-
(CH2)6-O-Man]2 
1.95 
2.00 
1.90 
2.00 
2.00 
1.90 
2.00 
2.80 
1.74 
1.80 
1.85 
1.90 
 
1.80 
 
1KWU 
1KWV 
1KWW 
1KWX 
1KWY 
1KWZ 
1KX0 
1KX1 
1KXA 
1KXB 
1KXC 
1KZD 
 
1KZE 
Mannose 
receptor 
human MR CTLD4 
 
 
mouse MR Cys-rich domain 
+GalNAc-4-SO4 
+ 3-SO4-Lewisa  
+ 3-SO4-Lewisx  
2.30 
2.30 
 
1.70 
2.20 
2.20 
1.90 
1EGG 
1EGI 
 
1DQG 
1DQO 
1FWV 
1FWU 
[205] 
 
 
[206] 
 
[207] 
NODs human NRLX1 2.65 3UN9 [59] 
RLRs human RIG-I CTD 
 
 
+5'-ppp dsRNA 
 
 
hRIG-I (∆CARD)+dsRNA 
+dsRNA+ADP 
ATPase domain of RIG-I 
+AMP-PNP 
duck RIG-I CTD 
dRIG-I helicase 
dRIG-I CARDs +helicase 
dRIG-I full length 
dRIG-I CTD+ dsRNA 
dRIG-I+dsRNA+ADP-AlF3   
hRIG-I+dsRNA+BeF3   
3.00 
 
NMR 
2.55 
2.60 
2.15 
2.50 
2.58 
2.80 
2.14 
1.44 
3.00 
3.40 
3.70 
4.00 
3.70 
2.90 
2QFB 
2QFD 
2RMJ 
3NCU 
3LRN 
3LRR 
2YKG 
4BPB 
4AY3 
TBK2 
4A2V 
4A2P 
4A2Q 
4A2W 
4A2X 
4A36 
3TMI 
 
[230] 
 
[231] 
[232] 
[233] 
 
[237] 
 
[238] 
[234] 
 
[236] 
 
 
 
 
[235] 
MDA5 human MDA5+dsRNA 3.56 4GL2 [241] 
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Figure Legends 
Figure 1.  The innate immune system operates largely in peripheral tissues, where it 
recognizes foreign pathogens. Upon binding of PAMPs to PRRs, the innate immune 
system is activated and provides a first line of defence against the invader. 
Subsequently the adaptive immune system is activated, and with help from the innate 
immune system, pathogen-specific antibodies and killer T cells are produced (Figure 
adapted from [11]). 
 
Figure 2.  Ten TLRs have been identified in humans, and are located either on the 
outer cell membrane or the membrane of endosomes within the cytoplasm of immune 
cells. When PAMPs bind to the ectodomain of the TLR, signals are transmitted into 
the cell via intracellular (TIR) domains [22], which bind and activate transcription 
factors (NFkB and/or members of the interferon-regulated factors (IRF)). The 
transcription factors promote expression of numerous genes that alter the activation 
state of the cell, as well as for inflammatory cytokines and chemokines that are 
exported and signal to other cells (see Figure 1). 
 
Figure 3. Domain architecture of representative human NLRs [47, 52]. 
Abbreviations: LRRs, leucine rich repeats for ligand sensing; NACHT, a nucleotide 
binding and oligomerization  domain; PYD, pyrin effector domain; BIR, baculovirus 
inhibitor repeat effector domain; CARD, caspase activation and recruitment effector 
domain; NBD, nucleotide binding domain; FIIND, function to find domain. 
 
Figure 4.  Domain structures of RLRs. RIG-1 and MDA-5 have the same domain 
architecture. Abbreviations: CARD, caspase activation and recruitment effector 
domain; CTD, C-terminal regulatory domain; HEL2i, helicase insertion domain; 
HEL1/2 helicase 1/helicase 2 ; P, pincer domain. 
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Figure 5. A, Characteristic LRR motif, and structure of one LRR module. Orange, ß-
strand; green, bridging loop. B, The typical horseshoe, or solenoid-like structure of a 
TLR ectodomain. C, The disulfide-rich capping modules at the N- (LRR-NT) and C-
terminus (LRR-CT). 
 
Figure 6. Single domain (left) and three-domain (red, green and blue, right) TLR sub-
classes. The characteristic Asn residues (show in orange/red/blue ball-and-stick) in 
each repeat motif, and the ladder of hydrogen-bonds (in light blue) they form are 
shown. 
 
Figure 7. Structures of lipoproteins Pam2Cys and Pam3Cys, and the lipid derivatives 
PE-DTPA and LTA. 
 
Figure 8. Structure of the TLR1/2-Pam3CSK4 complex; TLR2 (blue), TLR1 (green, 
lipid (red). View from the side with membrane below (left), and from the top of the 
complex looking down onto the membrane (not indicated) (right). 
 
Figure 9. The TLR1/2_Pam3CSK4 complex. A, The bound ligand situated near the 
center of the TLR1/2 protein-protein interface. B, Slice through the complex. The two 
ester-linked lipids project into a binding pocket in TLR2 (blue) and the amide-linked 
lipid into one in TLR1 (green). C, the lipid-binding cavity (with mesh) and entrance 
lies near LRR modules 10-12 (light blue). D, Hydrogen-bonding interactions (pink 
dotted) with the ligand head-group. 
 
Figure 10. Structures of the mTLR2-LTA and mTLR2-PE-DTPA complexes. A, The 
mTLR2-LTA complex. B, the LRR10 and 11 loops and position of the LTA ligand 
head-group are altered from those in the TLR1/2/Pam3CSK4 complex. C, The head 
group of bound DTPA (green) resembles that in the complex with LTA rather than 
that seen in the TLR1/2/Pam3CSK4 complex (orange). 
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Figure 11. Structure of the TLR2/6 heterodimer with bound lipopeptide Pam2CSK4 
(not shown). The hydrophobic core of the protein-protein interface is larger than in 
the TLR1/2 complex. 
 
Figure 12. Structural comparisons of the TLR2/6-Pam2CSK4 and TLR1/2-Pam3CSK4 
complexes. A, In both complexes, the two ester-linked lipid chains in Pam2CSK4 are 
inserted into a hydrophobic pocket on TLR2. B, Only a very restricted hydrophobic 
pocket is present in TLR6. C, This pocket in TLR1 is larger and contains the amide-
linked lipid chain in the ligand. 
 
Figure 13. Structure of TLR3 ectodomain. The LRR-NT and -CT modules, at the N- 
and C-termini, are highlighted. 
 
Figure 14. dsRNA:TLR3 signaling complex. A, Mouse TLR3 ectodomains form a 
dimer on the dsRNA. B, The dsRNA binding sites of TLR3. Residues within contact 
distance to the dsRNA include, at the C-terminal site, Asn515, Asn517, His539, Asn541 
and Arg544, which are all well conserved in vertebrates. The N-terminal interaction 
site is formed by His39, His60, Arg64, Phe84, Ser86, His108, Glu110. 
 
Figure 15. Structure of a cross-strand I:C base pair. 
 
Figure 16. Generic structure of LPS and lipid IVa from E. coli, and the synthetic 
antagonist Eritoran. No outer O-antigen polysaccharide is shown. Abbreviations: 
GlcN, 2-amino-2-deoxy-D-glucose; Kdo, 3-deoxy-D-manno-2-octulosonic acid; Hep, 
L-glycero-D-manno-heptose; Glc, D-glucose; Gal, D-galactose. 
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Figure 17. Structure of MD-2 with lipid IVa. A, The four lipid chains of lipid IVa are 
buried between the two ß-sheets in MD-2. B, Surface representation of the complex. 
C, Interactions between MD-2 and the head group (sugars (green/red) and phosphates 
(yellow/red)) of bound lipid IVa. 
 
Figure 18. Structure of the 1:1 TLR4/MD-2 complex with bound Eritoran (see text). 
 
Figure 19. Structure of the dimeric TLR4/MD-2/LPS signaling complex. TLR4 
chains, blue; MD-2 chains, orange; lipid A, red; and outer sugar/phosphates, pink (see 
section 2.4). 
 
Figure 20. Structure of the dimeric TLR4/MD-2/LPS signaling complex. A, Five 
lipid chains of LPS are buried and one (R2) is on the surface of MD-2. B, The 
TLR4/MD-2 interface. C, LPS sugar-TLR4 interactions. 
 
Figure 21. Structural comparison of LPS and antagonists bound to MD-2. The MD-2 
chains are superimposed. The relative positions of LPS and Eritoran (left), and LPS 
and lipid-IVa (right) are shown. 
 
Figure 22. Structural comparison of mTLR4/MD-2/LPS with mTLR4/MD-2/lipid 
IVa complexes. A, Structure of mTLR4/MD-2/LPS. B, Structure of mTLR4/MD-
2/lipid IVa. C, Orientations of lipid A (in LPS) and lipid IVa bound to mMD-2 in the 
two complexes. 
 
Figure 23. Structure of flagellin (FliC) fragment (res. 53-450 of the 494 residue FliC). 
A, Domain D1 (blue), domain D2 (green), domain D3 (yellow). B, Crystal packing of 
the FliC fragment in two orthogonal views. The repeat distances are labelled. 
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Figure 24. Structure of the engineered 2:2 TLR5/FliC complex. A, Two TLR5 chains 
(pink and orange) oriented tail-to-tail interact with two FliC (green and gray). B, The 
1:1 complex is mediated by the primary binding interface, and its homodimerization 
to the 2:2 complex by the secondary dimerization interface. C, The TLR5 structure in 
the complex with LRR modules numbered. D, The FliC structure with labeled helices 
involved in the binding interfaces. 
 
Figure 25. Structures of synthetic ligands for TLR7 and TLR8. 
 
Figure 26. Structures of human TLR8. A, Monomer structure of the hTLR8-CL097 
complex. B, Side view of the inactivate TLR8 dimer. C, Activated state after binding 
ligand CL097 (see also Figure 28). The distance between the Cα atoms of the C 
termini is shown. 
 
Figure 27. Ligand recognition by TLR8. Residues involved in the interaction of 
TLR8 with CL097 (A), CL075 (B) and R848 (C) are shown.  
 
Figure 28. Conformational changes in TLR8 induced by binding to agonistic ligands. 
The unliganded inactive form (A) is transformed into the activated form (B) upon 
ligand binding. 
 
Figure 29. A, Schematic representation of the domain organization of DC-SIGN and 
DC-SIGNR. B, repeat motifs in the neck region. Residues at a/d positions of the 
heptad repeat are highlighted. C, the CRDs are projected and held away from the 
membrane by the neck. 
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Figure 30. A, Four-helix bundle of the 23-amino acid repeat motif of the neck region 
of DC-SIGNR. The repeat motifs are linked through non-helical segments, including 
a Pro residue. B, Model of a neck fragment containing multiple 4-helix bundles, with 
the C-terminal CRD at the top [187]. C, Top view of the CRD with the first 4-helix 
bundle [185]. 
 
Figure 31. A, Structures of oligosaccharides recognized by DC-SIGN and DC-
SIGN/R. B, N-Linked high mannose structure. 
 
Figure 32. A, Structure of the CRD of DC-SIGN bound to GlcNAc2Man3. Cyan 
spheres are bound Ca2+ ions [188].  B, Interactions of the α1-3-linked branch with 
DC-SIGNR. Only key sugars are shown. Ca2+ coordination is shown by blue lines, 
hydrogen bonds as dashed lines. C, Interactions of α1-3-linked branch with DC-SIGN. 
The terminal GlcNAc1 forms a cross-link by forming the typical CTL interaction with 
the principal Ca2+ site of another CRD (only coordination bonds to the Ca2+ (gray) are 
shown). D, Interaction of the α1-6-linked branch with DC-SIGNR, including the 
cnetral (reducing) mannose (Man3). 
 
Figure 33. Structures of ligands used in structural studies of DC-SIGN and DC-
SIGNR [189]. 
 
Figure 34. A, Structure of DC-SIGN bound to LNFP-III (see Figure 33). B, 
Structurfe of Lewisx trisaccharide bound to DC-SIGNR. Ca2+ coordination is shown 
by pink lines, hydrogen bonds as dashed lines. Cyan spheres are bound Ca2+ ions. 
 
Figure 35. A, Domain structure of the mannose receptor. B, Organization of a typical 
soluble mannose binding protein. 
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Figure 36. Trimeric unit of the human mannose-binding protein. Side (A) and top (B) 
views. Pink spheres are bound Ca2+ ions; surrounding residues are highlighted. The 
coiled coil region is red. The N- and C-termini of one chain are indicated. 
 
Figure 37.  Structure of the CTLD4 domain of the MR (A) with extended loop, and 
comparison to rat mannose binding protein A (B) [205]. Cyan sphere is a bound Ca2+ 
ion. Disulfide bonds are in yellow. 
 
Figure 38. A, Cysteine-rich domain from the MR (Cys-MR). Disulfides are yellow 
ball-and-stick. B, Cys-MR complexed with 4-SO4-N-acetylgalactosamine. Sulfur 
atom in yellow, hydrogen bonds in blue dotted lines. 
 
Figure 39. Structure of cNLRX1. The monomer subunit is shown (top). The hexamer 
(bottom) is formed by trimerization of dimers (subunits A/A', B/B' and C/C'). The 
LRR modules in subunit A are labelled (Figure adapted from [59]). 
 
Figure 40.  A, Structure of RIG-I CTD bound to blunt-end 5'-PPP 12-mer ds-RNA. B, 
Interactions between the 5'-PPP and the CTD. Phosphates are yellow/red. The Phe853 
side chain, which stacks with the bases of the terminal base-pair, is highlighted. 
 
Figure 41. A, Domain organization of the RIG-I protein. The boxed region 
(∆CARDs) was crystallized. B, Overall structure of the RIG-I dsRNA complex. The 
domain coloring is that shown in A. C, Solvent accessible protein surface of the 
complex. 
 
Figure 42. A, Ternary complex of RIG-I (∆CARDs), 5'-PPP hairpin-RNA and ADP-
Mg2+. B, Interactions between the 5'-PPP and the CTD. Phosphates are yellow/red. In 
the hairpin RNA, G1 base-pairs with C20. 
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Figure 43. A, Structure of duck RIG-I-Hel (lacking CARDs and CTD domains) in an 
open conformation (PDB 4A2P), in which the HEL1 and HEL2 domains are not in 
direct contact [236]. In full length RIG-I, the CARDs would be linked to the N-
terminus of HEL1 and the CTD to the C-terminus of HEL2 (see Figure 41A). The 
bridging or pincer domain comprising two long α-helices connected by an ≈80o bend 
is shown in red. B, Structure of RIG-I lacking only the CARDs with dsRNA (PDB 
2YKG) [237]. The RIG-I protein completely surrounds the dsRNA, which is bound in 
a central cavity. C, A model for RIG-I activation (adapted from [236] and [237]). In 
the absence of RNA, RIG-I is in an autoinhibited open state. 5'-PPP-RNA is first 
captured by the CTD. Upon binding and/or hydrolysis of ATP the activated closed 
form is generated, competent for signaling through the CARDs. 
 
Figure 44. Structure of the MDA5∆N' protein bound to dsRNA (PDB 4GL2) [241]; 
left, top view; right, side view. The domains are colored as in Figure 4. The MDA5 
forms a ring around dsRNA, bound in the central cavity. The position of bound 
nucleotide analogue ADPNP is indicated. 
 
Figure 45. A, Top view of the MDA5∆N'-dsRNA complex showing the extensive 
interactions between HEL2i and CTD (HEL1 and HEL2 are gray, pincer domain red). 
B, The HEL2i-CTD interface with bound Zn2+. C, Left, the HEL2 loop (red) in 
MDA5∆N' is inserted into the major groove of dsRNA, which widens from 1.2 nm to 
1.8 nm. Right, the RIG-I loop binds to the end of the 5'-PPP-RNA. 
 
Figure 46. Oligomerization of full-length MDA5 on long dsRNA. Three models for 
the oligomers (I, II and III) that are consistent with experimental data. In the first two 
models, 2CARDs form a filament along or around the central MAD5 filament. 
Alternatively, 2CARDs may form discrete patches along the central MAD5 filament. 
Figure adapted from [241]. 
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Footnote 
§ Abbreviations: APC, antigen-presenting cell; BCR, B-cell receptor; BIR, 
baculovirus inhibitor repeat; CARD, caspase activation and recruitment domain; 
CIITA, class II transactivator; CRD, carbohydrate recognition domain; CTD, C-
terminal domain; CTL, C-type lectin; CTLD, C-type lectin (or lectin-like) domain; 
DC, dendritic cell; DC-SIGN(R), dendritic cell-specific intercellular adhesion 
molecule-grabbing nonintegrin (and the R variant); DTPA, 1,2-dimyristoyl-sn-
glycero-3-phospho-ethanolamine-N-diethylenetriaminepentaacetic acid; ECD, 
extracellular domain; FliC, flagellin; FNII, fibronectin type-II; GPI, glycosyl-
phosphatidyl-inositol; IFN, interferon; IRF, interferon-regulated factors; HEL1, 
helicase domain 1; LBP, LPS binding protein; LGP2, "laboratory of genetics and 
physiology 2"; LNFP-III, lacto-N-fucopentaose-III; LPS, lipopolysaccharide; LRR, 
leucine-rich repeats; LTA, lipoteichoic acid; MBP, mannose-binding protein; MHC-I 
and -II, major histocompatibility complex-I and -II; MDA5, "melanoma 
differentiation associated factor gene 5"; MPL, monophosphoryl lipid A; MR, 
mannose receptor; MLS, macrolide-lincosamide-streptogramin group; NACHT, a 
conserved domain found in "NAIP, CIITA, HET-E and TPI-1"; NAIP, NLR family 
apoptosis inhibitory protein; NOD, nucleotide-binding and oligomerization domain; 
NLR, Nod-like receptor; ODN, oligodeoxynucleotide; OM, outer membrane; PAMP, 
pathogen associated molecular pattern; PE, phosphatidylethanolamine; PGN, 
peptidoglycan; PPI, protein-protein interface;  PRR, pattern recognition receptor; 
PYD, pyrin domain; RIG, retinoic acid-inducible gene-I; RLR, RIG-like receptor; 
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TIR; “Toll IL-1 receptor”; TLR, Toll-like receptor; VLR, variable lymphocyte 
receptor. 
 
 
 
